View Filing Data

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Sep. 30, 2016	Nov. 11, 2016
Document And Entity Information
Entity Registrant Name	Imprimis Pharmaceuticals, Inc.
Entity Central Index Key	0001360214
Document Type	10-Q
Document Period End Date	Sep. 30, 2016
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		13,253,763
Trading Symbol	IMMY
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2016

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Current assets
Cash and cash equivalents	$ 2,362	$ 2,685
Restricted cash and short-term investments	450	150
Accounts receivable, net	2,233	840
Insurance receivable	841
Inventories	1,902	1,412
Prepaid expenses and other current assets	1,162	786
Total current assets	8,950	5,873
Property, plant and equipment, net	7,346	2,657
Intangible assets, net	2,994	3,135
Goodwill	2,227	2,466
TOTAL ASSETS	21,517	14,131
Current liabilities
Accounts payable and accrued expenses	3,795	3,407
Accrued payroll and related liabilities	1,291	1,200
Deferred revenue and customer deposits	55	65
Current portion of deferred acquisition obligation and accrued interest	205	198
Current portion of contingent acquisition obligation		483
Current portion of capital lease obligations, net of unamortized discount	434	21
Total current liabilities	5,780	5,374
Capital lease obligations, net of current portion and unamortized discount	1,439	1
Deferred acquisition obligation, net of current portion	104	258
Accrued expenses, net of current portion	585	500
Deferred tax liability	1,047	1,047
Note payable and paid-in-kind interest, net of unamortized debt discount	8,816	8,336
Convertible note payable, net of unamortized debt discount	914
TOTAL LIABILITIES	18,685	15,516
STOCKHOLDERS' EQUITY (DEFICIT)
Common stock, $0.001 par value, 90,000,000 shares authorized, 13,229,320 and 9,755,678 shares issued and outstanding at September 30, 2016 and December 31, 2015, respectively	13	10
Additional paid-in capital	73,568	56,369
Accumulated deficit	(70,749)	(57,764)
TOTAL STOCKHOLDERS' EQUITY (DEFICIT)	2,832	(1,385)
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)	$ 21,517	$ 14,131

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2016	Dec. 31, 2015
Statement of Financial Position [Abstract]
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	90,000,000	90,000,000
Common stock, shares issued	13,229,320	9,755,678
Common stock, shares outstanding	13,229,320	9,755,678

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Revenues:
Sales, net	$ 4,858	$ 2,682	$ 14,141	$ 6,161
License revenues	3	1	8	52
Total revenues	4,861	2,683	14,149	6,213
Cost of sales	(2,339)	(1,202)	(6,760)	(3,259)
Gross profit	2,522	1,481	7,389	2,954
Operating expenses:
Selling and marketing	1,797	1,813	5,967	4,455
General and administrative	5,018	3,104	13,355	8,327
Research and development	16	93	138	299
Impairment of intangible assets and goodwill	303		303
Total operating expenses	7,134	5,010	19,763	13,081
Loss from operations	(4,612)	(3,529)	(12,374)	(10,127)
Other income (expense):
Interest expense, net	(732)	(423)	(1,992)	(679)
Change in fair value of derivative liabilities			(113)
Other income, net	1,494		1,494	31
Total other income (expense), net	762	(423)	(611)	(648)
Net loss	$ (3,850)	$ (3,952)	$ (12,985)	$ (10,775)
Basic and diluted net loss per share of common stock	$ (0.29)	$ (0.41)	$ (1.05)	$ (1.13)
Weighted average number of shares of common stock outstanding, basic and diluted	13,471,004	9,603,541	12,404,328	9,501,730

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (12,985)	$ (10,775)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization of furniture and equipment	699	186
Amortization of intangible assets	262	264
Amortization of debt discount	829	175
Paid-in-kind added to principal of note payable	153	79
Non-cash gain on contingent acquisition obligations	(83)	(31)
Change in fair value of derivative liabilities	113
Impairment of intangible assets and goodwill	303
Stock-based compensation	2,989	2,317
Issuance of warrant related to litigation settlement	115
Changes in assets and liabilities, net of effects from acquisitions:
Accounts and insurance receivable	(2,162)	(221)
Inventories	(490)	(605)
Prepaid expenses and other current assets	(450)	(444)
Accounts payable and accrued expenses	1,648	845
Accrued payroll and related liabilities	93	349
Deferred revenue and customer deposits	(11)	19
NET CASH USED IN OPERATING ACTIVITIES	(8,977)	(7,842)
CASH FLOWS FROM INVESTING ACTIVITIES
Payments on Pharmacy Creations contingent acquisition obligation	(100)
Purchase of Central Allen Pharmacy, net of cash		(421)
Purchase of Park Compounding, net of cash		(3,005)
Investment in marketable securities	(300)
Investment in patent and trademark assets	(185)	(129)
Purchases of property, plant and equipment	(6,540)	(704)
NET CASH USED IN INVESTING ACTIVITIES	(7,125)	(4,259)
CASH FLOWS FROM FINANCING ACTIVITIES
Payments on capital lease obligations	(119)	(18)
Net proceeds from public equity offering	11,088
Payments on Park deferred acquisition obligation	(145)	(87)
Proceeds from note payable, net of issuance costs		9,303
Proceeds from convertible note payable, net of issuance costs	2,772
Proceeds from Essex leaseback, net of issuance costs	1,933
Net proceeds from ATM sales of common stock	195
Net proceeds from exercise of warrants and stock options	55	1,248
NET CASH PROVIDED BY (USED IN) FINANCING ACTIVITIES	15,779	10,446
NET CHANGE IN CASH AND CASH EQUIVALENTS	(323)	(1,655)
CASH AND CASH EQUIVALENTS, beginning of period	2,685	8,211
CASH AND CASH EQUIVALENTS, end of period	2,362	6,556
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Cash paid for income taxes	9	1
Cash paid for interest	984	414
SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING ACTIVITIES:
Fair value of embedded conversion feature recorded as debt discount and derivative liability	2,322
Reclassification of the fair value of the embedded conversion feature derivative liability to additional paid-in capital upon closing of the public equity offering	2,646
Reclassification of the fair value of the LSAF warrant from additional paid-in capital to derivative liability	675
Reclassification of the fair value of the LSAF warrant derivative liability to additional paid-in capital upon closing of the public equity offering	464
Issuance of common stock and fair value of deferred acquisition obligations related to the purchase of Park Compounding		1,016
Issuance of common stock and to settle contingent acquisition obligation related to the purchase of PC	302
Issuance of stock options for consulting services included in accounts payable and accrued expenses	23	39
Final fee on notes payable recorded as debt discount and included in accrued expenses		500
Estimated relative fair value of warrants issued in connection with note payable		840
Purchase of property, plant and equipment included in accounts payable and accrued expenses	$ 122

Description of Business and Basis of Presentation

9 Months Ended

Sep. 30, 2016

Accounting Policies [Abstract]

Description of Business and Basis of Presentation

NOTE 1. DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION

Company and Background

Imprimis Pharmaceuticals, Inc. (together with its subsidiaries, unless the context indicates or otherwise requires, the “Company” or “Imprimis”) is a national leader in the development, production and dispensing of novel compounded pharmaceuticals. The Company is focused on patient outcomes and affordability by offering high quality customizable compounded drugs in all 50 states. Imprimis is headquartered in San Diego, California and operates three pharmacy facilities located in California, New Jersey and Pennsylvania, which may be referred hereinafter collectively as our “ImprimisRx compounding facilities.”

Basis of Presentation

Imprimis has prepared the accompanying unaudited condensed consolidated financial statements in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for audited financial statements. In the opinion of management, all adjustments (consisting of only normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the three and nine months ended September 30, 2016 are not necessarily indicative of the results that may be expected for the year ending December 31, 2016 or for any other period. For further information, refer to the Company’s audited consolidated financial statements and footnotes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2015.

The accompanying condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.

Summary of Significant Accounting Policies

9 Months Ended

Sep. 30, 2016

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

The following represents an update for the nine months ended September 30, 2016 to the significant accounting policies described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2015.

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and judgments that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting periods. Significant estimates made by management are, among others, allowance for doubtful accounts and contractual adjustments, realizability of inventories, valuation of deferred taxes, goodwill and intangible assets, recoverability of long-lived assets and goodwill, valuation of contingent acquisition obligations and deferred acquisition obligations, valuation of notes payable and derivative liabilities, and valuation of stock-based compensation issued to employees and non-employees. Actual results could differ from those estimates.

Going Concern and Liquidity

The Company has incurred significant operating losses and negative cash flows from operations since its inception. The Company incurred net losses of $12,985 and $10,775 for the nine months ended September 30, 2016 and 2015, respectively, and had an accumulated deficit of $70,749 and $57,764 as of September 30, 2016 and December 31, 2015, respectively. In addition, the Company used cash in operating activities of $8,977 and $7,842 for the nine months ended September 30, 2016 and 2015, respectively.

While there is no assurance, the Company believes its existing cash resources and restricted investments of approximately $2,812 at September 30, 2016, along with $841 in proceeds received from insurance claims (see Note 12), is not sufficient to sustain the Company’s planned level of operations for at least the next twelve months. The Company’s history of recurring losses, and uncertainties as to whether the Company’s operations will become profitable, raise substantial doubt about its ability to continue as a going concern.

The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with GAAP which contemplates continuation of the Company as a going concern and the realization of assets and satisfaction of liabilities in the normal course of business. The ability of the Company to continue its operations is dependent on the execution of management’s plans, which include the raising of capital through the debt and/or equity markets, until such time that funds provided by operations are sufficient to fund working capital requirements. The condensed consolidated financial statements contained in this report do not include any adjustments related to the recoverability of assets or classifications of liabilities that might be necessary should the Company be unable to continue as a going concern. If the Company is not able to continue as a going concern, it would likely not be able to realize its assets at values comparable to the carrying value or the fair value estimates reflected in the balances set out in the condensed consolidated financial statements.

The Company may seek to increase liquidity and capital resources by one or more measures, to the extent necessary. These measures may include, but are not limited to, the following: obtaining financing through the issuance of equity, debt, or convertible securities; sale and leaseback arrangements; entering into leasing facilities; and working to increase revenue growth through pharmacy sales. There is no guarantee that the Company will be able to obtain capital when needed on terms it deems as acceptable, or at all.

Concentrations of Credit Risk

The Company places its cash with financial institutions deemed by management to be of high credit quality. The Federal Deposit Insurance Corporation (“FDIC”) provides basic deposit coverage with limits up to $250 per owner, per deposit category, with the same institution. At September 30, 2016, the Company had approximately $2,111 in cash deposits in excess of FDIC limits.

Accounts Receivable

Accounts receivable are stated net of allowances for doubtful accounts and contractual adjustments. The accounts receivable balance primarily includes amounts due from customers that the Company has invoiced or from third-party providers (e.g., insurance companies and governmental agencies), which payment has not been received. Charges to bad debt are based on both historical write-offs and specifically identified receivables. Contractual adjustments are determined by the amount expected to be collected from third-party providers. Accounts receivable are presented net of allowances for doubtful accounts and contractual adjustments in the amount of $272 and $180 as of September 30, 2016 and December 31, 2015, respectively.

Goodwill and Intangible Assets

Patents and trademarks are recorded at cost and capitalized at a time when the future economic benefits of such patents and trademarks become more certain. At that time, the Company capitalizes third party legal costs and filing fees associated with obtaining and prosecuting claims related to its patents and trademarks. Once the patents have been issued, the Company amortizes these costs over the shorter of the legal life of the patent or its estimated economic life, generally 20 years, using the straight-line method. Trademarks are an indefinite life intangible asset and are assessed for impairment based on future projected cash flows as further described below.

The Company reviews its goodwill and indefinite-lived intangible assets for impairment as of January 1 of each year and when an event or a change in circumstances indicates the fair value of a reporting unit may be below its carrying amount. Events or changes in circumstances considered as impairment indicators include but are not limited to the following:

	●	significant underperformance of the Company’s business relative to expected operating results;

	●	significant adverse economic and industry trends;

	●	significant decline in the Company’s market capitalization for an extended period of time relative to net book value; and

	●	expectations that a reporting unit will be sold or otherwise disposed.

The goodwill impairment test consists of a two-step process as follows:

Step 1. The Company compares the fair value of each reporting unit to its carrying amount, including the existing goodwill. The fair value of each reporting unit is determined using a discounted cash flow valuation analysis. The carrying amount of each reporting unit is determined by specifically identifying and allocating the assets and liabilities to each reporting unit based on headcount, relative revenues or other methods as deemed appropriate by management. If the carrying amount of a reporting unit exceeds its fair value, an indication exists that the reporting unit’s goodwill may be impaired and the Company then performs the second step of the impairment test. If the fair value of a reporting unit exceeds its carrying amount, no further analysis is required.

Step 2. If further analysis is required, the Company compares the implied fair value of the reporting unit’s goodwill, determined by allocating the reporting unit’s fair value to all of its assets and its liabilities in a manner similar to a purchase price allocation, to its carrying amount. If the carrying amount of the reporting unit’s goodwill exceeds its fair value, an impairment loss will be recognized in an amount equal to the excess. See the impairment amount recorded to goodwill during the three months ended September 30, 2016 below.

Impairment of Long-Lived Assets

Long-lived assets, such as furniture and equipment, purchased intangibles subject to amortization and patents and trademarks, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future cash flows, an impairment charge is recognized in the amount by which the carrying amount of the asset exceeds the fair value of the asset. Assets to be disposed of would be separately presented in the consolidated balance sheet and reported at the lower of the carrying amount or fair value less costs to sell, and are no longer depreciated. The assets and liabilities of a disposal group classified as held-for-sale would be presented separately in the appropriate asset and liability sections of the consolidated balance sheet, if material.

In September 2016, the Company decided to cease operations at its Texas facility, and began winding down the operations. Based on current projections regarding future cash flows of the Texas facility and the related subsidiary, the evaluation resulted in an impairment of $64 related to intangible assets and $239 related to goodwill, recorded to impairment of intangible assets and goodwill on the Condensed Consolidated Statements of Operations during the three and nine months ended September 30, 2016.

Revenue Recognition and Deferred Revenue

The Company recognizes revenues when all of the following criteria have been met: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred; (3) the selling price is fixed and determinable; and (4) collectability is reasonably assured. The Company’s revenues consist of sales of certain of the Company’s proprietary compounded drug formulations and non-proprietary formulations and products.

Product Revenues

Determination of criteria (3) and (4) is based on management’s judgments regarding the fixed nature of the selling prices of the products delivered and the collectability of those amounts. Estimated returns and allowances and other adjustments are provided for in the same period during which the related sales are recorded. The Company will defer any revenues received for a product that has not been delivered or is subject to refund until such time that the Company and the customer jointly determine that the product has been delivered and no refund will be required.

License Revenues

License arrangements may consist of non-refundable upfront license fees, data transfer fees, research reimbursement payments, exclusive license rights to patented or patent pending compounds, technology access fees, and various performance or sales milestones. These arrangements can be multiple element arrangements.

Non-refundable fees that are not contingent on any future performance by the Company and require no consequential continuing involvement on the part of the Company are recognized as revenue when the license term commences and the licensed data, technology, compounded drug preparation and/or other deliverable is delivered. Such deliverables may include physical quantities of compounded drug preparations, design of the compounded drug preparations and structure-activity relationships, the conceptual framework and mechanism of action, and rights to the patents or patent applications for such compounded drug preparations. The Company defers recognition of non-refundable fees if it has continuing performance obligations without which the technology, right, product or service conveyed in conjunction with the non-refundable fee has no utility to the licensee and that are separate and independent of the Company’s performance under the other elements of the arrangement. In addition, if the Company’s continued involvement is required, through research and development services that are related to its proprietary know-how and expertise of the delivered technology or can only be performed by the Company, then such non-refundable fees are deferred and recognized over the period of continuing involvement. Guaranteed minimum annual royalties are recognized on a straight-line basis over the applicable term.

Debt Issuance Costs and Debt Discount

Debt issuance costs and the debt discount are recorded net of notes payable and capital lease obligations in the condensed consolidated balance sheets. Amortization expense of debt issuance costs and the debt discount is calculated using the effective interest method over the term of the debt and is recorded in interest expense in the accompanying condensed consolidated statements of operations.

Fair Value Measurements

Fair value measurements are determined based on the assumptions that market participants would use in pricing an asset or liability. GAAP establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. The established fair value hierarchy prioritizes the use of inputs used in valuation methodologies into the following three levels:

●	Level 1: Applies to assets or liabilities for which there are quoted prices (unadjusted) for identical assets or liabilities in active markets. A quoted price in an active market provides the most reliable evidence of fair value and must be used to measure fair value whenever available.

●	Level 2: Applies to assets or liabilities for which there are significant other observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data.

●	Level 3: Applies to assets or liabilities for which there are significant unobservable inputs that reflect a reporting entity’s own assumptions about the assumptions that market participants would use in pricing an asset or liability. For example, Level 3 inputs would relate to forecasts of future earnings and cash flows used in a discounted future cash flows method.

At September 30, 2016 and December 31, 2015, the Company did not have any financial assets or liabilities that are measured on a recurring basis. At September 30, 2016 and December 31, 2015, the Company’s financial instruments included cash and cash equivalents, restricted short-term investments, accounts receivable, accounts payable and accrued expenses, accrued payroll and related liabilities, customer deposits, deferred acquisition obligations, notes payable and capital leases. The carrying amount of these financial instruments, except for deferred acquisition obligations, notes payable and capital leases, approximates fair value due to the short-term maturities of these instruments. The Company’s restricted short-term investments are carried at amortized cost, which approximates fair value. Based on borrowing rates currently available to the Company, the carrying values of the deferred acquisition obligations, notes payable and capital leases, approximate their respective fair values.

Derivative Instruments

The Company accounts for free-standing derivative instruments and hybrid instruments that contain embedded derivative features as either assets or liabilities in the condensed consolidated balance sheets and are measured at fair value with gains or losses recognized in earnings. Embedded derivatives that are not clearly and closely related to the host contract are bifurcated and are recognized at fair value with changes in fair value recognized as either a gain or loss in earnings. The Company determines the fair value of derivative instruments and hybrid instruments based on available market data using appropriate valuation models, giving consideration to all of the rights and obligations of each instrument.

The Company estimates the fair value of derivative instruments and hybrid instruments using various techniques (and combinations thereof) that are considered to be consistent with the objective of measuring fair value. In selecting the appropriate technique, the Company considers, among other factors, the nature of the instrument, the market risks that it embodies and the expected means of settlement. The Company generally uses the Black-Scholes-Merton option pricing model, adjusted for the effect of dilution, because it embodies all of the requisite assumptions (including trading volatility, estimated terms, dilution and risk-free rates) necessary to fair value these instruments. Estimating the fair value of derivative financial instruments requires the development of significant and subjective estimates that may, and are likely to, change over the duration of the instrument with related changes in internal and external market factors. Increases in the trading price of the Company’s common stock and increases in fair value during a given financial quarter result in the application of non-cash derivative expense. Conversely, decreases in the trading price of the Company’s common stock and decreases in fair value during a given financial quarter would result in the application of non-cash derivative income.

Third Party Billing and Collection Agreements

In connection with its acquisition of South Coast Specialty Compounding, Inc. D/B/A Park Compounding (“Park”), the Company entered into a billing and collection agreement with a third party to assist in the billing and collection of workers’ compensation claims. Under the terms of the agreement, the Company is obligated to pay a fixed fee to the third party equal to 55% of the amounts billed and collected under the workers’ compensation claims. The Company accrues for such fees in accounts payable and accrued expenses in the accompanying condensed consolidated balance sheets. Total billing and collection management expense under this agreement for the three and nine months ended September 30, 2016 were $0 and $24, respectively, and $7 and $28, for the three and nine months ended September 30, 2015, respectively, and is included in selling and marketing expenses in the accompanying condensed consolidated statements of operations. The amounts due under the agreement as of September 30, 2016 and December 31, 2015 were $30 and $81, respectively.

Stock-Based Compensation

All stock-based payments to employees, directors and consultants, including grants of stock options, warrants, restricted stock units (“RSUs”) and restricted stock, are recognized in the condensed consolidated financial statements based upon their estimated fair values. The Company uses the Black-Scholes-Merton option pricing model and Monte Carlo Simulation to estimate the fair value of stock-based awards. The estimated fair value is determined at the date of grant. The financial statement effect of forfeitures is estimated at the time of grant and revised, if necessary, if the actual effect differs from those estimates.

The Company’s accounting policy for equity instruments issued to consultants and vendors in exchange for goods and services follows Financial Accounting Standards Board (“FASB”) guidance. As such, the value of the applicable stock-based compensation is periodically remeasured and income or expense is recognized during the vesting terms of the equity instruments. The measurement date for the estimated fair value of the equity instruments issued is the earlier of (i) the date at which a commitment for performance by the consultant or vendor is reached or (ii) the date at which the consultant or vendor’s performance is complete. In the case of equity instruments issued to consultants, the estimated fair value of the equity instrument is primarily recognized over the term of the consulting agreement. According to FASB guidance, an asset acquired in exchange for the issuance of fully vested, nonforfeitable equity instruments should not be presented or classified as an offset to equity on the grantor’s balance sheet once the equity instrument is granted for accounting purposes. Accordingly, the Company records the estimated fair value of nonforfeitable equity instruments issued for future consulting services as prepaid stock-based consulting expenses in its condensed consolidated balance sheets.

Income Taxes

The Company accounts for income taxes under the provisions of FASB Accounting Standards Codification (“ASC”) 740, Income Taxes, or ASC 740. As of September 30, 2016, there were no unrecognized tax benefits included in the condensed consolidated balance sheet that would, if recognized, affect the effective tax rate. The Company’s practice is to recognize interest and/or penalties related to income tax matters in income tax expense. The Company had no accrual for interest or penalties in its condensed consolidated balance sheets at September 30, 2016 and December 31, 2015, and has not recognized interest and/or penalties in the condensed consolidated statements of operations for the three and nine months ended September 30, 2016 and 2015. The Company is subject to taxation in the United States, New Jersey, Texas, Pennsylvania and California. The Company’s tax years since 2000 are subject to examination by the federal and state tax authorities due to the carryforward of unutilized net operating losses.

Basic and Diluted Net Loss per Common Share

Basic net loss per common share is computed by dividing net loss attributable to common stockholders for the period by the weighted average number of common shares outstanding during the period. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders for the period by the weighted average number of common and common equivalent shares, such as stock options and warrants, outstanding during the period.

Basic and diluted net loss per share is computed using the weighted average number of shares of common stock outstanding during the period. Common stock equivalents (using the treasury stock or “if converted” method) from deferred acquisition obligations, convertible note payable, stock options, unvested RSUs and warrants were 4,424,397 and 3,382,512 at September 30, 2016 and 2015, respectively, and are excluded from the calculation of diluted net loss per share for all periods presented because the effect is anti-dilutive. Included in the basic and diluted net loss per share calculation were RSUs awarded to our CEO, Mark Baum, that have vested, but issuance and delivery of shares has not occurred and RSUs awarded to directors that had vested, but the issuance and delivery of the shares are deferred until the director resigns. The number of shares underlying these vested RSUs at September 30, 2016 and 2015 was 281,283 and 39,880, respectively.

The following table shows the computation of basic and diluted net loss per share of common stock for the three and nine months ended September 30, 2016 and 2015:

	For the			For the			For the			For the
	Three Months Ended			Three Months Ended			Nine Months Ended			Nine Months Ended
	September 30, 2016			September 30, 2015			September 30, 2016			September 30, 2015

Numerator – net loss	$	(3,850	)	$	(3,952	)	$	(12,985	)	$	(10,775	)
Denominator – weighted average number of shares outstanding, basic and diluted		13,471,004			9,603,541			12,404,328			9,501,730
Net loss per share, basic and diluted	$	(0.29	)	$	(0.41	)	$	(1.05	)	$	(1.13	)

Recently Issued Accounting Pronouncements

In May 2014, the FASB issued Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers. This updated guidance supersedes the current revenue recognition guidance, including industry-specific guidance. The updated guidance introduces a five-step model to achieve its core principal of the entity recognizing revenue to depict the transfer of goods or services to customers at an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The updated guidance is effective for interim and annual periods beginning after December 15, 2016, and early adoption is not permitted. In July 2015, the FASB decided to delay the effective date of ASU 2014-09 until December 15, 2017. The FASB also agreed to allow entities to choose to adopt the standard as of the original effective date. The Company is currently evaluating which transition method it will adopt and the expected impact of the updated guidance, but does not believe the adoption of the updated guidance will have a significant impact on its condensed consolidated financial statements.

In August 2014, the FASB issued new accounting guidance which defines management’s responsibility to assess an entity’s ability to continue as a going concern, and to provide related footnote disclosures in certain circumstances. This guidance will be effective for annual periods ending after December 15, 2016 and interim periods within annual periods beginning after December 15, 2016. Early adoption is permitted for annual or interim reporting periods for which the financial statements have not previously been issued. The Company will apply the guidance and disclosure provisions of the new standard upon adoption in its 2016 annual consolidated financial statements.

In February 2016, the FASB issued ASU 2016-02, Leases, which requires the lease rights and obligations arising from lease contracts, including existing and new arrangements, to be recognized as assets and liabilities on the balance sheet. ASU 2016-02 is effective for reporting periods beginning after December 15, 2018 with early adoption permitted. While the Company is still evaluating ASU 2016-02, the Company expects the adoption of ASU 2016-02 to have a material effect on the Company’s consolidated financial condition due to the recognition of the lease rights and obligations as assets and liabilities. The Company does not expect ASU 2016-02 to have a material effect on the Company’s results of operations and cash flows.

In January 2016, the FASB issued ASU 2016-01, Financial Instruments: Recognition and Measurement of Financial Assets and Financial Liabilities, which addresses certain aspects of recognition, measurement, presentation and disclosure of financial statements. This guidance will be effective in the first quarter of fiscal year 2019 and early adoption is not permitted. The Company is currently evaluating the impact that this guidance will have on its condensed consolidated financial statements.

In March 2016, the FASB issued ASU 2016-09, Compensation-Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting, which addresses certain aspects of accounting for share-based payment award transactions. This guidance will be effective in the first quarter of fiscal year 2017 and early adoption is permitted. The Company is currently evaluating the impact that this guidance will have on its condensed consolidated financial statements.

In July 2015, the FASB issued ASU 2015-11, Simplifying the Measurement of Inventory, which requires entities to measure most inventory “at the lower of cost and net realizable value (“NRV”),” thereby simplifying the current guidance under which an entity must measure inventory at the lower of cost or market. Under the new guidance, inventory is “measured at the lower of cost and net realizable value,” which eliminates the need to determine replacement cost and evaluate whether it is above the ceiling (NRV) or below the floor (NRV less a normal profit margin). The guidance defines NRV as the “estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation.” The guidance is effective for annual periods beginning after December 15, 2016, and interim periods therein. Early application is permitted. The Company is evaluating the impact of adoption of this guidance on its financial position and results of operations.

Restricted Cash and Short-Term Investments

9 Months Ended

Sep. 30, 2016

Cash and Cash Equivalents [Abstract]

Restricted Cash and Short-Term Investments

NOTE 3. RESTRICTED CASH AND SHORT-TERM INVESTMENTS

The restricted cash and short-term investments at September 30, 2016 and December 31, 2015 consisted of certificates of deposit, which are classified as held-to-maturity, and funds held in a money market account. At September 30, 2016 and December 31, 2015, the restricted short-term investments were recorded at amortized cost, which approximates fair value.

At September 30, 2016 and December 31, 2015, the certificates of deposit and funds held in a money market account of $450 and $150 were classified as a current asset. These certificates of deposit and money market account funds are required as collateral under the Company’s corporate credit card agreement and additional security for the Company’s office space and New Jersey facility lease, and the certificates of deposit automatically renew every twelve months.

Inventories

9 Months Ended

Sep. 30, 2016

Inventory Disclosure [Abstract]

Inventories

NOTE 4. INVENTORIES

Inventories are comprised of finished compounded formulations, over-the-counter and prescription retail pharmacy products, commercial pharmaceutical products, related laboratory supplies and active pharmaceutical ingredients. The composition of inventories as of September 30, 2016 and December 31, 2015 was as follows:

	September 30, 2016		December 31, 2015
Raw materials	$	801	$	775
Finished goods		1,101		637
Total inventories	$	1,902	$	1,412

Prepaid Expenses and Other Current Assets

9 Months Ended

Sep. 30, 2016

Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]

Prepaid Expenses and Other Current Assets

NOTE 5. PREPAID EXPENSES AND OTHER CURRENT ASSETS

Prepaid expenses and other current assets consisted of the following:

	September 30, 2016		December 31, 2015
Prepaid insurance	$	443	$	297
Other prepaid expenses		613		370
Deposits and other current assets		106		119
Total prepaid expenses and other current assets	$	1,162	$	786

Intangible Assets and Goodwill

9 Months Ended

Sep. 30, 2016

Goodwill and Intangible Assets Disclosure [Abstract]

Intangible Assets and Goodwill

NOTE 6. INTANGIBLE ASSETS AND GOODWILL

The Company’s intangible assets at September 30, 2016 consisted of the following:

	Amortization
	periods			Accumulated						Net
	(in years)	Cost		amortization			Impairment			Carrying value
Patents	17-19 years	$	168	$	(6	)	$	-		$	162
Trademarks	Indefinite		201		-			-			201
Customer relationships	3-15 years		2,998		(488	)		(15	)		2,495
Trade name	5 years		16		(6	)		(1	)		9
Non-competition clause	3-4 years		294		(161	)		(20	)		113
State pharmacy licenses	25 years		45		(4	)		(28	)		13
		$	3,722	$	(665	)	$	(64	)	$	2,994

Amortization expense for intangible assets for the three and nine months ended September 30, 2016 was as follows:

	For the		For the		For the		For the
	Three Months Ended		Three Months Ended		Nine Months Ended		Nine Months Ended
	September 30, 2016		September 30, 2015		September 30, 2016		September 30, 2015
Patents	$	4	$	-	$	5	$	-
Customer relationships		60		66		191		195
Trade name		-		1		2		2
Non-competition clause		16		22		62		66
State pharmacy licenses		-		-		2		1
	$	79	$	88	$	262	$	264

Estimated future amortization expense for the Company’s intangible assets at September 30, 2016 is as follows:

Remainder of 2016	$	90
2017		357
2018		216
2019		212
2020		210
Thereafter		1,908
	$	2,994

Changes to the carrying value of the Company’s goodwill during the nine months ended September 30, 2016 was as follows:

Balance at December 31, 2015		2,466
Impairment related to Texas facility cessation		(239	)
Balance at September 30, 2016	$	2,227

- Definition

The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.

+ References + Details

Accounts Payable and Accrued Expenses

9 Months Ended

Sep. 30, 2016

Payables and Accruals [Abstract]

Accounts Payable and Accrued Expenses

NOTE 7. ACCOUNTS PAYABLE AND ACCRUED EXPENSES

Accounts payable and accrued expenses consisted of the following:

	September 30, 2016			December 31, 2015
Accounts payable	$	3,222		$	3,185
Deferred rent		429			63
Accrued interest (see Note 8)		108			90
Accrued exit fee for note payable (see Note 8)		500			500
Building lease liability(1)		121			46
Other accrued expenses (2)		-			23
Total accounts payable and accrued expenses		4,380			3,907
Less: Current portion		(3,795	)		(3,407	)
Non-current total accrued expenses	$	585		$	500

	(1)	In September 2014, the Company relocated its primary operations to a 7,565 square foot office facility in San Diego, California. In February 2015, the Company entered into a sublease agreement to sublet 3,874 square feet of its previously occupied offices through the remaining term of the lease at a monthly rent amount of $8. The Company recognized a loss of approximately $117 during the year ended December 31, 2014 related to the estimated remaining lease liability, net of expected sublease income, of the previously occupied offices. In September 2016, the Company decided to cease operations at its Texas location and started steps to wind down operations. The Company recognized a loss of $121 during the nine months ended September 30, 2016 related to the estimated remaining lease liability. The obligations were discounted based on current prevailing market rates.

	(2)	The amount consists of a $23 stock-based compensation accrual at December 31, 2015 related to stock options to be granted for consulting services provided. The stock options were granted during the nine months ended September 30, 2016 and the $23 was recorded to additional paid-in-capital.

Debt

9 Months Ended

Sep. 30, 2016

Debt Disclosure [Abstract]

Debt

NOTE 8. DEBT

Senior Note - 2015

On May 11, 2015, the Company entered into a loan and security agreement (the “Loan Agreement”) with IMMY Funding LLC, an affiliate of Life Sciences Alternative Funding LLC (the “Lender”), as lender and collateral agent. Pursuant to the terms of the Loan Agreement, as amended in January 2016, the Lender made available to the Company a term loan in the aggregate principal amount of up to $10,000, all of which was drawn on May 11, 2015. The term loans bear interest at a fixed per-annum rate of 12.5% and allows for 2% of the interest to be paid-in-kind until either February 2017 or May 2017, depending upon the Company’s ability to meet certain revenue or cash balance measures. The Company is permitted to pay interest only for the first three years and after the end of the interest-only period, the Company will be required to pay interest, plus repayments of the principal amount of the term loans, in 36 equal monthly installments. The interest-only period may be reduced to 20 months if the Company does not meet certain minimum revenue or cash balance requirements and the Company would be required to pay interest, plus repayments of the principal amount of the term loan, in 24 equal monthly installments. All amounts owed under the Loan Agreement, including a final fee of 5% of the aggregate principal amount of the term loan, will be due on the earlier of May 11, 2021, or 24 months after the end of the interest-only period. The Company incurred expenses of approximately $735 in connection with the Loan Agreement. The final fee and expenses are being amortized as interest expense over the term of the debt using the interest method and the related liability of $500 for the final fee is included in accrued expenses (see Note 7) in the accompanying condensed consolidated balance sheets.

Pursuant to the terms of the Loan Agreement, the Company is bound by certain affirmative covenants setting forth actions that the Company must take during the term of the Loan Agreement, including, among others, certain information delivery requirements, obligations to maintain certain insurance and certain notice requirements. Additionally, the Company is bound by certain negative covenants setting forth actions that the Company may not take during the term of the Loan Agreement without the Lender’s consent, including, among others, disposing of certain of the Company’s or its subsidiaries’ business or property, incurring certain additional indebtedness, entering into certain merger, acquisition or change of control transactions, paying certain dividends or distributions on or repurchasing any of the Company’s capital stock, or incurring any lien or other encumbrance on the Company’s or its subsidiaries’ assets, subject to certain permitted exceptions. Upon the occurrence of an event of default under the Loan Agreement (subject to cure periods for certain events of default), all amounts owed by the Company thereunder may be declared immediately due and payable by the Lender. Events of default include, among others, the following: the occurrence of certain bankruptcy events; the failure to make payments under the Loan Agreement when due; the occurrence of a material adverse change in the business, operations or condition of the Company or any of its subsidiaries; the breach by the Company or its subsidiaries of certain of their material agreements with third parties; the initiation of certain regulatory enforcement actions against the Company or its subsidiaries; the rendering of certain types of fines or judgments against the Company or its subsidiaries; any breach by the Company or its subsidiaries of any covenant (subject to cure periods for certain covenants) made in the Loan Agreement; and the failure of any representation or warranty made by the Company or its subsidiaries in connection with the Loan Agreement to be correct in any material respect when made.

The Company’s obligations under the Loan Agreement are guaranteed on a secured basis by its wholly owned subsidiaries. Each of the Company and its subsidiaries has granted the Lender a security interest in substantially all of its personal property, rights and assets, including intellectual property rights and equity ownership, to secure the payment of all amounts owed under the Loan Agreement.

In connection with the Loan Agreement, the Company has issued to the Lender a warrant to purchase up to 125,000 shares of the Company’s common stock, which is exercisable immediately, had an exercise price of $7.85 per share upon issuance and has a term of 10 years. The relative fair value of the warrants was approximately $840 and was estimated using the Black-Scholes-Merton option pricing model with the following assumptions: fair value of the Company’s common stock at issuance of $7.97 per share; ten-year contractual term; 109% volatility; 0% dividend rate; and a risk-free interest rate of 1.25%. The relative fair value of the warrants was recorded as a debt discount, decreasing notes payable and increasing additional paid-in capital on the accompanying condensed consolidated balance sheet. The debt discount is being amortized to interest expense over the term of the debt using the interest method. As described further, this warrant was amended in January 2016. For the three and nine months ended September 30, 2016 and 2015, debt discount amortization related to the Loan Agreement was $110 and $327 and $105 and $175, respectively.

Convertible Senior Note – 2016

On January 22, 2016, the Company entered into a note purchase agreement (the “NPA”) with, and issued an 8.00% Convertible Senior Secured Note in the principal amount of $3,000 (the “Convertible Note”) to, the Lender. Pursuant to the terms of the NPA, on the date thereof, the Company issued the Convertible Note to the Lender and, as consideration therefor, the Lender paid the Company in cash the full principal amount of the Convertible Note. The Company incurred expenses of approximately $228 in connection with the Convertible Note and was recorded as a debt discount. The debt discount is being amortized as interest expense over the term of the debt using the interest method.

Pursuant to the terms of the Convertible Note, the Company is obligated to pay interest on the principal amount of the Convertible Note monthly in cash at a fixed per-annum rate of 8.00%, and the Company is obligated to repay the full principal amount of the Convertible Note in cash on May 11, 2021. The Company is permitted to redeem the Convertible Note prior to its maturity at any time on or after March 1, 2018 for cash purchase prices equal to 109% - 105% of the outstanding principal amount of the Convertible Note, depending on the date of redemption. The Convertible Note was initially convertible by the holder at any time into shares of the Company’s common stock at an effective conversion price of approximately $5.90 and subject to anti-dilution adjustment upon the Company’s first equity financing while the Convertible Note is outstanding in which it receives gross proceeds of at least $3,000, if such equity financing is completed at a per share price that is less than the conversion rate of the Convertible Note, and also subject to adjustment upon stock combinations or splits, certain recapitalizations, stock or cash dividends or other distributions of property or equity rights. Additionally, in the event of certain change of control events affecting the Company, the Company may be required, at the option of the Lender, to repurchase the Convertible Note in cash for the greater of 105% of the outstanding principal amount of the Convertible Note or the value of the shares of common stock issuable upon conversion of the Convertible Note. The relative fair value of the conversion feature was $2,322 and was recorded as a debt discount, decreasing notes payable and increasing additional paid-in capital on the accompanying condensed consolidated balance sheet (see also Note 10). The debt discount is being amortized to interest expense over the term of the debt using the interest method. For the three and nine months ended September 30, 2016, debt discount amortization related to the Convertible Note was $155 and $464, respectively.

In connection and concurrently with the execution of the NPA and the issuance of the Convertible Note, the Company and the Lender also entered into an amendment (the “Loan Agreement Amendment”) to the Loan Agreement (see above). The Loan Agreement Amendment modifies the terms of the Loan Agreement in order to eliminate the potential borrowing of a second term loan thereunder and to permit the Company to issue the Convertible Note. Additionally, the Company and the Lender entered into an amendment (the “Warrant Amendment”) to the warrants that were issued to the Lender in connection with the Loan Agreement. The Warrant Amendment modifies the terms of the warrants in order to reduce the exercise price thereof to $5.90 per share, which is consistent with the initial conversion rate of the Convertible Note, and to add an anti-dilution adjustment provision that is consistent with the same such provision in the Convertible Note.

On March 16, 2016, upon the closing of the Offering (see Note 10) and pursuant to the anti-dilution adjustment provisions of the Convertible Note and the Warrant Amendment, the effective conversion price of the Convertible Note was adjusted to approximately $3.60, and the exercise price of the warrants was adjusted to $3.60 per share (see also Note 10 for further accounting discussion of the warrant exercise price and conversion provisions and related derivative liabilities).

Notes payable at September 30, 2016 was as follows:

	September 30, 2016
Senior Note - 2015	$	10,000
Convertible Senior Note - 2016		3,000
Add: Interest paid-in-kind		283
Less: Discount on notes		(3,553	)
Less: Current portion		-
Long-term portion	$	9,730

Future minimum payments as of September 30, 2016 are as follows:

	Amount

Remainder of 2016	$	437
2017		1,435
2018		2,981
2019		4,423
2020		4,424
Thereafter		5,711
Total minimum payments		19,411
Less: amount representing interest and interest paid-in-kind		(6,411	)
Notes payable, gross		13,000
Add: interest paid-in-kind		283
Less: unamortized discount		(3,553	)
Note payable and interest paid-in-kind, net of unamortized debt discount	$	9,730

Capital Lease Obligation

9 Months Ended

Sep. 30, 2016

Leases [Abstract]

Capital Lease - Essex

NOTE 9. CAPITAL LEASE OBLIGATION

On August 9, 2016, the Company entered into a commercial lease agreement (the “Lease Agreement”) with Essex Capital Corporation (“Essex”). Pursuant to the terms of the Lease Agreement, the Company sold certain equipment (the “Equipment”) to Essex for a total purchase price of approximately $2,000, which was leased back to the Company under a thirty-six month term net basis lease with monthly payments of approximately $64. The fair value and undepreciated amounts of equipment sold and leased under the Lease Agreement totaled approximately $2,000. The lease term may be extended for an additional twelve month period in the event the Company achieves certain financial milestones. The Company has the right to purchase the Equipment from Essex upon the expiration of the Lease Agreement for a purchase price equal to the Equipment’s then fair market value, with such fair market value not to exceed fifteen percent of the original Equipment cost. If the equipment is not purchased, the Company may automatically extend the lease on a month-to-month basis or return the equipment and terminate the Lease Agreement. The Company expects to purchase the Equipment at the end of the term of the lease and included the final payment amount of $300 in its future payment schedule. The Company also incurred expenses of approximately $67 in connection with the Lease Agreement. The issuance costs were recorded as a discount. The discount is being amortized as interest expense over the term of the lease using the interest method. The Company used an interest rate of 16.8% for calculation of the present value of the future minimum payments under the Lease Agreement and is amortizing the debt issuance costs at a rate of 1.8%. For the three and nine months ended September 30, 2016, debt discount amortization related to the Lease Agreement was $37.

The Company has also leased other equipment under capital leases with an interest rate of 4.25% per annum. At September 30, 2016, future payments under the Company’s capital leases were as follows:

	Amount
Remainder of 2016	$	194
2017		775
2018		773
2019		751
Total minimum lease payments		2,493
Less: amount representing interest payments		(590	)
Present value of future minimum lease payment		1,903
Less: current portion		(434	)
Less: unamortized discount		(30	)
Capital lease obligation, net of current portion and unamortized discount	$	1,439

Stockholders' Equity (Deficit) and Stock-Based Compensation

9 Months Ended

Sep. 30, 2016

Equity [Abstract]

Stockholders' Equity (Deficit) and Stock-Based Compensation

NOTE 10. STOCKHOLDERS’ EQUITY (DEFICIT) AND STOCK-BASED COMPENSATION

Common Stock

In March 2016, the Company entered into an underwriting agreement (the “Underwriting Agreement”) with National Securities Corporation and several other underwriters, under which the Company sold in a firm-commitment public offering (the “Offering”), 3,335,000 shares of the Company’s common stock at $3.60 per share. The Offering closed on March 16, 2016. The Company received net proceeds of $11,088, after deducting the underwriting discount and the offering expenses payable by the Company.

In November 2015, the Company entered into a Controlled Equity Offering^SM sales agreement (the “Sales Agreement”) with Cantor Fitzgerald & Co., as agent (“Cantor Fitzgerald”), pursuant to which the Company may offer and sell, from time to time through Cantor Fitzgerald, shares of our common stock having an aggregate offering price as set forth in the Sales Agreement and a related prospectus supplement filed with the Securities and Exchange Commission. The Company agreed to pay Cantor Fitzgerald a cash commission of 3.0% of the aggregate gross proceeds from each sale of shares under the Sales Agreement. In March 2016, in connection with the Offering, the Company reduced the amount available for sale pursuant to the Sales Agreement with Cantor Fitzgerald to shares of its common stock having an aggregate offering price of $2,625. The Company sold 48,642 shares of common stock and received net proceeds of $195, after deducting $16 for sales commission and offering expenses, under the Sales Agreement during the nine months ended September 30, 2016, leaving an aggregate of $1,885 available for future sales of shares thereunder as of September 30, 2016.

In May 2016, 200,000 shares of the Company’s common stock underlying RSUs issued to its CEO, Mark L. Baum vested, but delivery of these shares has not yet occurred.

In May 2016, we issued 75,000 shares of the Company’s common stock, with a fair value of $302, as a contingent payment related to the acquisition of PC (defined below) (see also Note 12).

During the nine months ended September 30, 2016, 33,154 shares of the Company’s common stock underlying RSUs issued to directors vested, but the issuance and delivery of these shares are deferred until the director resigns.

During the nine months ended September 30, 2016, the Company issued a total of 15,000 shares of common stock as a result of option exercises. The Company received $55 in cash proceeds for the issuance of the shares of common stock upon the exercise pursuant to exercise provisions of stock options to purchase 15,000 shares of common stock with exercise price of $3.68 per share.

Preferred Stock

At September 30, 2016, the Company had 5,000,000 shares of preferred stock, $0.001 par value, authorized and no shares of preferred stock issued and outstanding.

Stock Option Plan

On September 17, 2007, the Company’s Board of Directors and stockholders adopted the Company’s 2007 Incentive Stock and Awards Plan, which was subsequently amended on November 5, 2008, February 26, 2012, July 18, 2012, May 2, 2013 and September 27, 2013 (as amended, the “Plan”). As of September 30, 2016, the Plan provides for the issuance of a maximum of 5,000,000 shares of the Company’s common stock. The purpose of the Plan is to attract and retain directors, officers, consultants, advisors and employees whose services are considered valuable, to encourage a sense of proprietorship and to stimulate an active interest of such persons in the Company’s development and financial success. Under the Plan, the Company is authorized to issue incentive stock options intended to qualify under Section 422 of the Internal Revenue Code, non-qualified stock options, restricted stock units and restricted stock. The Plan is administered by the Compensation Committee of the Company’s Board of Directors.

Stock Options

A summary of stock option activity under the Plan for the nine months ended September 30, 2016 is as follows:

	Number of shares			Weighted Avg. Exercise Price		Weighted Avg. Remaining Contractual Life		Aggregate Intrinsic Value
Options outstanding - January 1, 2016		1,544,026		$	5.74
Options granted		502,350		$	4.02
Options exercised		(15,000	)	$	3.68
Options cancelled/forfeit		(60,313	)	$	8.02
Options outstanding - September 30, 2016		1,971,063			6.25		6.28	$	178,525
Options exercisable		760,071			6.26		5.86	$	176,250
Options vested and expected to vest		1,850,552			6.25		6.27	$	178,298

The aggregate intrinsic value in the table above represents the total pre-tax amount of the proceeds, net of exercise price, which would have been received by option holders if all option holders had exercised and immediately sold all options with an exercise price lower than the market price on September 30, 2016, based on the closing price of the Company’s common stock of $3.81 on that date. The aggregate intrinsic value of stock options exercised during the nine months ended September 30, 2016 was approximately $29.

During the nine months ended September 30, 2016, the Company granted stock options to certain employees and consultants. The stock options were granted with an exercise price equal to the current market price of the Company’s common stock, as reported by the securities exchange on which the common stock was then listed, at the grant date and have contractual terms of 10 years. Vesting terms for options granted to employees and consultants during the nine months ended September 30, 2016 typically included one of the following vesting schedules: 25% of the shares subject to the option vest and become exercisable on the first anniversary of the grant date and the remaining 75% of the shares subject to the option vest and become exercisable quarterly in equal installments thereafter over three years; or 100% vesting associated with the provision or completion of services provided under contracts with consultants. Certain option awards provide for accelerated vesting if there is a change in control (as defined in the Plan) and in the event of certain modifications to the option award agreement.

The fair value of each option award is estimated on the date of grant using the Black-Scholes-Merton option pricing model. The expected volatility is based on the historical volatilities of the common stock of the Company and comparable publicly traded companies based on the Company’s belief that it currently has limited relevant historical data regarding the volatility of its stock price on which to base a meaningful estimate of expected volatility. The expected term of options granted was determined in accordance with the “simplified approach,” as the Company has limited, relevant, historical data on employee exercises and post-vesting employment termination behavior. The expected risk-free interest rate is based on the U.S. Treasury yield for a period consistent with the expected term of the option in effect at the time of the grant. The financial statement effect of forfeitures is estimated at the time of grant and revised, if necessary, if the actual effect differs from those estimates. For option grants to employees and directors, the Company assigns a forfeiture factor of 10%. These factors could change in the future, which would affect the determination of stock-based compensation expense in future periods. Utilizing these assumptions, the fair value is determined at the date of grant.

The table below illustrates the fair value per share determined by the Black-Scholes-Merton option pricing model with the following assumptions used for valuing options granted to employees:

	2016
Weighted-average fair value of options granted	$	3.91
Expected terms (in years)		5.81 - 6.11
Expected volatility		101 - 107	%
Risk-free interest rate		1.07 - 1.70	%
Dividend yield		-

The table below illustrates the fair value per share determined by the Black-Scholes-Merton option pricing model with the following assumptions used for valuing options granted to consultants:

	2016
Weighted-average fair value of options granted	$	4.37
Expected terms (in years)		10.00
Expected volatility		104	%
Risk-free interest rate		1.14	%
Dividend yield		-

The following table summarizes information about stock options outstanding and exercisable at September 30, 2016:

	Options Outstanding						Options Exercisable
			Weighted
			Average		Weighted				Weighted
			Remaining		Average				Average
	Number		Contractual		Exercise		Number		Exercise
Range of Exercise Prices	Outstanding		Life in Years		Price		Exercisable		Price
$2.40		125,000		5.32	$	2.40		125,000	$	2.40
$3.74 - $4.50		678,123		7.89	$	4.06		194,005	$	4.29
$5.49 - $7.99		949,353		5.26	$	7.54		234,328	$	6. 80
$8.06 - $8.99		213,557		6.37	$	8.92		201,708	$	8.95
$42.80		5,030		3.87	$	42.80		5,030	$	42.80
		1,971,063		6.28	$	6.25		760,071	$	6.26

As of September 30, 2016, there was approximately $5,111 of total unrecognized compensation expense related to unvested stock options granted under the Plan. That expense is expected to be recognized over the weighted-average remaining vesting period of 3.3 years. The stock-based compensation expense for all stock options was $471 and $1,772 during the three and nine months ended September 30, 2016, respectively.

Restricted Stock Units

RSU awards are granted subject to certain vesting requirements and other restrictions, including performance and market-based vesting criteria. The grant date fair value of the RSUs, which has been determined based upon the market value of the Company’s common stock on the grant date, is expensed over the vesting period of the RSUs. Unvested portions of RSUs issued to consultants are remeasured on an interim basis until vesting criteria is met.

In April 2016, the Company granted performance-based RSU awards to its CEO, Mark L. Baum, of up to 1,050,000 performance stock units and to its CFO, Andrew R. Boll, of up to 157,500 performance units. The performance stock units will vest on the fifth anniversary of the grant date, subject to Mr. Baum’s and Mr. Boll’s continued employment with the Company, respectively, and may vest earlier if the Company achieves and maintains certain stock price targets during the five year period following the grant date or upon a change in control if the performance-based equity award is not assumed, continued or substituted for by the acquiring entity. The market-based accelerated vesting criteria are broken into five equal tranches and require that the Company achieve and maintain certain stock price targets ranging from $9 per share to $15 per share during the five-year period following the grant date. These market-based accelerated vesting conditions and share amounts (in aggregate) are set forth below:

Tranche	Number of shares	Target share price
Tranche 1	230,000 shares	$9.00 or greater
Tranche 2	230,000 shares	$10.00 or greater
Tranche 3	230,000 shares	$12.00 or greater
Tranche 4	230,000 shares	$14.00 or greater
Tranche 5	287,500 shares	$15.00 or greater

For each respective tranche to vest the following conditions must be met: (i) the Company’s common stock must have an official closing price at or above the target share price for the respective tranche (each such date, a “Trigger Date”); (ii) during the period that includes the Trigger Date and the immediately following 19 trading days (the “Measurement Period”), the arithmetic mean of the 20 closing prices of the Company’s common stock during the Measurement Period must be at or above the target share price for such tranche; and (iii) with certain limited exceptions, the executive must be in service with the Company through the date of vesting.

Concurrent with the issuance of the performance-based restricted stock unit awards, Mr. Baum agreed to forfeit 1,050,000 RSUs subject to performance-based vesting granted to him in May 2013 and Mr. Boll agreed to forfeit 157,500 RSUs subject to performance-based vesting granted to him in February 2015. As a result, the issuance of the performance-based RSUs awarded in April 2016 have been treated as modifications of the RSUs granted to Mr. Baum in May 2013 and Mr. Boll in February 2015 for accounting purposes. The Company used a lattice binomial model to estimate a derived service period of 33 months related to the performance-based vesting grants and used the following assumptions:

	2016
Market price	$	3.98
Contractual terms (in years)		5.00
Expected volatility		102	%
Risk-free interest rate		1.04	%
Dividend yield		-

A summary of the Company’s RSU activity and related information for the nine months ended September 30, 2016 is as follows:

	Number of RSUs			Weighted Average Grant Date Fair Value
RSUs unvested - January 1, 2016		1,487,961		$	3.18
RSUs granted		1,270,950		$	2.25
RSUs vested		(236,326	)	$	8.56
RSUs cancelled/forfeit		(1,217,017	)	$	1.95
RSUs unvested at September 30, 2016		1,305,568		$	2.45

As of September 30, 2016, the total unrecognized compensation expense related to unvested RSUs was approximately $3,874, which is expected to be recognized over a weighted-average period of 2.0 years, based on estimated and actual vesting schedules of the applicable RSUs. The stock-based compensation for RSUs during the three and nine months ended September 30, 2016 was $313 and $1,237, respectively.

Warrants

From time to time, the Company issues warrants to purchase shares of the Company’s common stock to investors, lenders (see Note 8), underwriters, settlement agreements and other non-employees for services rendered or to be rendered in the future.

A summary of warrant activity for the nine months ended September 30, 2016 is as follows:

	Number of Shares Subject to Warrants Outstanding		Weighted Avg. Exercise Price

Warrants outstanding - January 1, 2016		240,688	$	7.41
Granted		40,000		3.75
Exercised		-
Expired		-
Warrants outstanding and exercisable - September 30, 2016		280,688	$	5.20
Weighted average remaining contractual life of the outstanding warrants in years - September 30, 2016		5.19

The table below illustrates the fair value per share determined by the Black-Scholes-Merton option pricing model with the following assumptions used for valuing warrants granted related to settlement agreements:

	2016
Weighted-average fair value of warrants granted		2.88
Expected terms (in years)		5
Expected volatility		106	%
Risk-free interest rate		0.79	%
Dividend yield		-

A list of the warrants outstanding as of September 30, 2016 is included in the following table:

	Warrants Outstanding					Warrants Exercisable
		Warrants		Exercise		Warrants		Expiration
Warrant Series	Issue Date	Outstanding		Price		Exercisable		Date
Lender warrants (see Note 8)	5/11/2015		125,000	$	3.60		125,000		5/11/2025
Underwriter warrants	2/7/2013		55,688	$	5.25		55,688		2/7/2018
Settlement warrants	8/16/2016		40,000	$	3.75		40,000		8/16/2021
Warrants issued to investor relations consultant	7/19/2013		60,000	$	8.50		60,000		7/19/2018
			280,688	$	5.20		280,688

The Company recorded stock-based compensation related to equity instruments granted to employees, directors and consultants as follows:

	For the		For the		For the		For the
	Three Months Ended		Three Months Ended		Nine Months Ended		Nine Months Ended
	September 30, 2016		September 30, 2015		September 30, 2016		September 30, 2015
Employees - selling and marketing	$	102	$	106	$	348	$	281
Employees - general and administrative		600		754		2,465		1,791
Directors - general and administrative		62		96		176		204
Consultants - selling and marketing		-		-		-		41
Other - general and administrative		115		-		115		-
Total	$	879	$	956	$	3,104	$	2,317

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74567-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(d))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

+ Details

Derivative Instruments

9 Months Ended

Sep. 30, 2016

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Derivative Instruments

NOTE 11. DERIVATIVE INSTRUMENTS

During the nine months ended September 30, 2016, the Company modified certain common stock purchase warrants issued in conjunction with debt which are detachable, or free standing, instruments. The warrants were considered a derivative liability upon modification and the estimated fair value of the warrants was reclassified from equity to liabilities. In addition, the Company recorded a derivative liability and debt discount associated with the estimated fair value of the embedded conversion feature in the Convertible Note (see Note 8). Both instruments contained a provision which allowed for one-time adjustments to their exercise or conversion prices. The one-time adjustment occurred upon the closing of the Company’s underwritten public offering of its common stock (see Note 10), on March 16, 2016, whereby the conversion and exercise prices were adjusted from $5.90 to $3.60 per share. At the time of the one-time adjustment, the Company reclassified the derivative liabilities to equity based on their estimated fair value at that time. The Company estimated the fair value of the derivative liabilities utilizing Level 3 inputs. The Company used the Black-Scholes-Merton option pricing model as it embodies all of the requisite assumptions (including trading volatility, remaining term to maturity, market price, strike price, and risk-free rates) necessary to value these instruments.

The table below illustrates the fair value per share determined by the Black-Scholes-Merton option pricing model with the following assumptions used for valuing derivative liabilities:

	2016
Expected volatility	103 - 111	%
Risk-free interest rate	1.22 - 1.70	%
Dividend yield	-

The Company estimated expected terms based on the remaining contractual life of the instruments on the date of the fair value measurement. The warrant expires on May 11, 2025 and the convertible note matures on May 11, 2021.

The following table provides a reconciliation of all liabilities measured at fair value using Level 3 significant unobservable inputs:

	September 30, 2016
Warrant derivative liability:
Balance at January 1, 2016	$	-
Modification of warrant and reclassification from equity to liabilities		675
Change in fair value		(211	)
Reclassification from liabilities to equity upon closing of public equity offering		(464	)
Balance at June 30, 2016	$	-

Embedded conversion feature derivative liability:
Balance at January 1, 2016	$	-
Embedded conversion feature in Convertible Note issued		2,322
Change in fair value		324
Reclassification from liabilities to equity upon closing of public equity offering		(2,646	)
Balance at September 30, 2016	$	-

- Definition

The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 30
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6441202&loc=d3e80720-113993

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4C
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5624171-113959

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=64837297&loc=d3e41620-113959

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4B
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5624163-113959

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5579240-113959

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4D
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5624177-113959

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=35736893&loc=d3e80784-113994

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=64837297&loc=d3e41641-113959

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5579245-113959

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4H
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5624258-113959

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=35736893&loc=d3e80748-113994

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4K
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5708775-113959

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4J
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5708773-113959

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4A
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5618551-113959

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1B
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5580258-113959

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4E
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5624181-113959

Reference 17: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 25
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6886632&loc=d3e76258-113986

Reference 18: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=64837297&loc=d3e41638-113959

Reference 19: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(n))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

+ Details

Commitments and Contingencies

9 Months Ended

Sep. 30, 2016

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

NOTE 12. COMMITMENTS AND CONTINGENCIES

Contingent Acquisition Obligation

On April 1, 2014, the Company acquired all of the outstanding membership interests of Pharmacy Creations, LLC (“PC”). The sellers of PC, are entitled to receive certain payments, including contingent consideration upon certain conditions, if PC earns revenue of between $3,500 and $7,500 during the 12 month period ending March 31, 2016, an aggregate of that number of shares of Imprimis common stock equal to the amount that such revenue exceeds $3,500 divided by 18.5882, rounded down to the lower whole number (not to exceed 215,190 shares). The estimated fair value of the contingent acquisition obligation was $483 and included in the contingent acquisition obligation in the accompanying condensed balance sheet at December 31, 2015. During May 2016, the Company paid the sellers of PC $100 in cash and 75,000 shares of its common stock with a fair value of $302, as payment in full related to the contingent acquisition obligation. Related to the payment of the contingent acquisition obligation the Company recorded a gain of $0 and $81 during the three and nine months ended September 30, 2016, respectively, which is included in other income in the accompanying condensed consolidated statement of operations.

Legal

Urigen, et. al, Litigation

On October 2014, the Company entered into a license agreement (the “Urigen License”) with Urigen Pharmaceuticals, Inc. (“Urigen”) for a license of certain U.S. patents and patent applications to develop and sell in the U.S. Urigen’s URG101 product, a heparin and alkalinized lidocaine compounded formulation for the prevention or treatment of disorders of the lower urinary tract. The Company, as the plaintiff, filed a civil action in the San Diego Superior Court against Urigen in December 2015, wherein the Company outlined serious concerns regarding material failures and inaccuracies of the representation and warranties provided by Urigen in the Urigen License, which have affected the Company’s ability to realize the expected benefit of the Urigen License. Urigen filed a cross-complaint in April 2016 for breach of contract asserting unpaid royalties totaling $698 and requesting a decree to cancel the Urigen Agreement. The Company filed another complaint in May 2016 with the U.S. District Court for the Southern District of California for declaratory judgment of the invalidity of the core patent filing related to Urigen’s URG 101. In June 2016, the Company received notice from Urigen of their election to terminate the Urigen License. In November 2016, the Company and Urigen entered into a settlement and mutual release agreement whereby all parties agreed to settle all disputes related to the Urigen License and associated litigation matters, the Company agreed to make a one-time payment to Urigen related to past sales of Urigen’s URG101 product and to cease selling the URG101 product over a certain period of time. The Company recorded a gain related to the settlement with Urigen totaling $551 which is included in other income, net in the accompanying condensed consolidated statement of operations.

Corwin, Kammer, et. al. Litigation

In February 2014, Robert Kammer (“Kammer”), the Company’s Chairman of the Board, filed a lawsuit in the San Diego Superior Court against Merlyn Corwin (“Corwin”) to enforce his contract rights related to a settlement agreement the parties had previously entered into involving shares of the Company’s common stock. Corwin filed an answer to the complaint in March 2014 and in June 2014 filed the first amended cross complaint adding the Company as a cross-defendant. In August 2014, Corwin filed a seconded amended cross complaint (the “SACC”) which added Mark Baum (“Baum”), the Company’s Chief Executive Officer, and an individual who previously provided consulting services to the Company as additional cross-defendants. The SACC alleged numerous causes of action including securities fraud, concealment, misrepresentations, inducement of misrepresentations, rescission – undue influence, intentional infliction of emotional distress and declaratory relief of invalidity of the settlement agreement. In September 2014, the Company and Baum filed an anti-strategic lawsuit against public participation motion (“Anti-SLAPP”), arguing all allegations in the SACC were based on protected activity under the litigation privilege. Kammer also filed an Anti-SLAPP motion in October 2014. In November 2014, the Company, Baum and Kammer were granted both Anti-SLAPP motions, with the ruling judge deciding that the parties successfully demonstrated that the allegations arose from activity protected by the litigation privilege. The judge further found that the evidence Corwin relied upon in her arguments failed to demonstrate a probability that she could prevail on any of the claims. The court then ordered Corwin to pay the Company’s and Baum’s attorney fees and the case was dismissed. In May 2015, Corwin filed an appeal and in November 2015, the appellate court reversed the Anti-SLAPP decision of the trial court. In April 2016, the Company and Baum filed a demurrer to the SACC. The court ordered a ruling on the demurrer in June 2016, dismissing most of the causes of action against Baum and the Company, but leaving the claim for fraud by concealment and intentional infliction of emotional distress. In August 2016, all parties related to this litigation entered into a settlement and mutual release agreement, whereby all parties agreed to settle all disputes and release one another of any legal claims. The Company issued 40,000 at-the-money warrants (see Note 10) as part of the settlement consideration. The fair value of the warrant and associated legal expenses were recorded in general and administrative expenses and netted against estimated accruals recorded prior to September 30, 2016 in the accompanying condensed consolidated statement of operations.

General and Other

In the ordinary course of business, the Company may face various claims brought by third parties and the Company may, from time to time, make claims or take legal actions to assert the Company’s rights, including intellectual property disputes, contractual disputes and other commercial disputes. Any of these claims could subject the Company to litigation. Management believes the outcomes of currently pending claims are not likely to have a material effect on the Company’s consolidated financial position and results of operations.

Indemnities

In addition to the indemnification provisions contained in the Company’s charter documents, the Company generally enters into separate indemnification agreements with each of the Company’s directors and officers. These agreements require the Company, among other things, to indemnify the director or officer against specified expenses and liabilities, such as attorneys’ fees, judgments, fines and settlements, paid by the individual in connection with any action, suit or proceeding arising out of the individual’s status or service as the Company’s director or officer, other than liabilities arising from willful misconduct or conduct that is knowingly fraudulent or deliberately dishonest, and to advance expenses incurred by the individual in connection with any proceeding against the individual with respect to which the individual may be entitled to indemnification by the Company. The Company also indemnifies its lessors in connection with its facility leases for certain claims arising from the use of the facilities. These indemnities do not provide for any limitation of the maximum potential future payments the Company could be obligated to make. Historically, the Company has not incurred any payments for these obligations and, therefore, no liabilities have been recorded for these indemnities in the accompanying condensed consolidated balance sheets.

Insurance Claims

In June 2016, the Company’s Texas based facility was damaged related to a malfunction with the property’s sprinkler system. The Company commenced restoration efforts and filed claims for damages under its insurance policies, including claims related to business interruption. During the three and nine months ended September 30, 2016, the Company recorded the insurance claim of $861 in other income, net in the condensed consolidated statements of operations which reflected amounts payable by its insurance carrier related to the claims filed for property damage and business interruption. During the nine months ended September 30, 2016 $20 was paid and at September 30, 2016, $841 was included in insurance receivable in the accompanying condensed consolidated balance sheet.

Asset Purchase, License and Commission Agreements

The Company has acquired intellectual property rights related to certain proprietary innovations from certain inventors (the “Inventors”) through multiple asset purchase, license and commission agreements. In consideration for the acquisition of the intellectual property rights, the Company is obligated to make certain milestone payments related to patent and regulatory filings to the Inventors and also make payments, in one instance a minimum annual amount, based on certain percentages of revenues and net sales amounts, as defined within the respective agreements. During the three and nine months ended September 30, 2016, the Company recognized $91 and $452, respectively, and $48 and $50, during the three and nine months ended September 30, 2015, respectively, in expense amounts related to these agreements. Such amounts are included in cost of sales and sales and marketing expenses in the accompanying condensed consolidated statements of operations.

Segment Information and Concentrations

9 Months Ended

Sep. 30, 2016

Segment Reporting [Abstract]

Segment Information and Concentrations

NOTE 13. SEGMENT INFORMATION AND CONCENTRATIONS

The Company operates its business on the basis of a single reportable segment, which is the business of developing proprietary drug therapies and providing such therapies through sterile and non-sterile pharmaceutical compounding services. The Company’s chief operating decision-maker is the Chief Executive Officer, who evaluates the Company as a single operating segment.

The Company categorizes revenues by geographic area based on selling location. All operations are currently located in the U.S.; therefore, total revenues for 2016 and 2015 are attributed to the U.S. All long-lived assets at September 30, 2016 and December 31, 2015 are located in the U.S.

The Company sells its compounded formulations to a large number of customers. Less than 10% of the Company’s total pharmacy sales were derived from a single customer for the three and nine months ended September 30, 2016 and 2015.

The Company receives its active pharmaceutical ingredients from three main suppliers. These suppliers collectively accounted for 76% and 72% during the three and nine months ended September 30, 2016, respectively, and 49% and 55% during the three and nine months ended September 30, 2015, respectively, of active pharmaceutical ingredient purchases.

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8981-108599

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9038-108599

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 33
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8971-108599

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8595-108599

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8380-108599

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 35
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8984-108599

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9031-108599

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9054-108599

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8538-108599

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 29
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8864-108599

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8924-108599

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8906-108599

+ Details

Subsequent Events

9 Months Ended

Sep. 30, 2016

Subsequent Events [Abstract]

Subsequent Events

NOTE 14. SUBSEQUENT EVENTS

The Company has performed an evaluation of events occurring subsequent to September 30, 2016 through the filing date of this Quarterly Report. Based on its evaluation, nothing other than the events described below needs to be disclosed.

In October 2016, the Company issued 16,076 shares of its common stock in connection with RSUs that had been awarded to a non-employee director and had vested, but were not issued and settled until the resignation of the director on September 20, 2016.

The Company sold 8,400 shares of common stock and received net proceeds of $18, after deducting $1 for sales commission and offering expenses, under the Sales Agreement.

In October 2016, the Company entered into a purchase and supply agreement the specialty pharmacy division of a leading pharmacy care services company. Pursuant to the terms of the agreement, the Company will provide the specialty pharmacy with compounded pharmaceutical products from its Imprimis Cares formulary of low-cost compounded therapeutic alternatives. The Company has not yet begun to make substantive amount of sales under this agreement, although it expects that sales will begin to increase to a meaningful level during the last two quarters of 2017.

Described further in Note 12, in November 2016, the Company and Urigen entered into a settlement and mutual release agreement whereby all parties agreed to settle all disputes related to the Urigen License and associated litigation matters, the Company agreed to make a one-time payment to Urigen related to past sales of Urigen’s URG101 product and to cease selling the URG101 product over a certain period of time. The Company recorded a gain related to the settlement with Urigen totaling $551 during the nine months ended September 30, 2016.

Described further in Note 12, the Company filed claims for damages under its insurance policies, including claims related to property damage and business interruption related to its Texas facility. In November 2016, the Company and its insurance carrier agreed to a total payment amount for settlement of the claims of $861. During the nine months ended September 30, 2016 $20 was paid and $840 was paid in November 2016. The total claim amount consisted of $44 related to property damage and $818 connected to business interruption, less a $1 deductible.

Summary of Significant Accounting Policies (Policies)

9 Months Ended

Sep. 30, 2016

Accounting Policies [Abstract]

Use of Estimates

Use of Estimates

Going Concern and Liquidity

Going Concern and Liquidity

Concentrations of Credit Risk

Concentrations of Credit Risk

Accounts Receivable

Accounts Receivable

Goodwill and Intangible Assets

Goodwill and Intangible Assets

	●	significant underperformance of the Company’s business relative to expected operating results;

	●	significant adverse economic and industry trends;

	●	significant decline in the Company’s market capitalization for an extended period of time relative to net book value; and

	●	expectations that a reporting unit will be sold or otherwise disposed.

The goodwill impairment test consists of a two-step process as follows:

Impairment of Long-Lived Assets

Impairment of Long-Lived Assets

Revenue Recognition and Deferred Revenue

Revenue Recognition and Deferred Revenue

Product Revenues

License Revenues

Debt Issuance Costs and Debt Discount

Debt Issuance Costs and Debt Discount

Fair Value Measurements

Fair Value Measurements

●	Level 1: Applies to assets or liabilities for which there are quoted prices (unadjusted) for identical assets or liabilities in active markets. A quoted price in an active market provides the most reliable evidence of fair value and must be used to measure fair value whenever available.

●	Level 2: Applies to assets or liabilities for which there are significant other observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data.

●	Level 3: Applies to assets or liabilities for which there are significant unobservable inputs that reflect a reporting entity’s own assumptions about the assumptions that market participants would use in pricing an asset or liability. For example, Level 3 inputs would relate to forecasts of future earnings and cash flows used in a discounted future cash flows method.

Derivative Instruments

Derivative Instruments

Third Party Billing and Collection Agreements

Third Party Billing and Collection Agreements

Stock-Based Compensation

Stock-Based Compensation

Income Taxes

Income Taxes

Basic and Diluted Net Loss per Common Share

Basic and Diluted Net Loss per Common Share

The following table shows the computation of basic and diluted net loss per share of common stock for the three and nine months ended September 30, 2016 and 2015:

	For the			For the			For the			For the
	Three Months Ended			Three Months Ended			Nine Months Ended			Nine Months Ended
	September 30, 2016			September 30, 2015			September 30, 2016			September 30, 2015

Numerator – net loss	$	(3,850	)	$	(3,952	)	$	(12,985	)	$	(10,775	)
Denominator – weighted average number of shares outstanding, basic and diluted		13,471,004			9,603,541			12,404,328			9,501,730
Net loss per share, basic and diluted	$	(0.29	)	$	(0.41	)	$	(1.05	)	$	(1.13	)

Recently Issued Accounting Pronouncements

Recently Issued Accounting Pronouncements

Summary of Significant Accounting Policies (Tables)

9 Months Ended

Sep. 30, 2016

Accounting Policies [Abstract]

Schedule of Basic and Diluted Earnings Per Common Share

The following table shows the computation of basic and diluted net loss per share of common stock for the three and nine months ended September 30, 2016 and 2015:

	For the			For the			For the			For the
	Three Months Ended			Three Months Ended			Nine Months Ended			Nine Months Ended
	September 30, 2016			September 30, 2015			September 30, 2016			September 30, 2015

Numerator – net loss	$	(3,850	)	$	(3,952	)	$	(12,985	)	$	(10,775	)
Denominator – weighted average number of shares outstanding, basic and diluted		13,471,004			9,603,541			12,404,328			9,501,730
Net loss per share, basic and diluted	$	(0.29	)	$	(0.41	)	$	(1.05	)	$	(1.13	)

Inventories (Tables)

9 Months Ended

Sep. 30, 2016

Inventory Disclosure [Abstract]

Schedule of Inventories

The composition of inventories as of September 30, 2016 and December 31, 2015 was as follows:

	September 30, 2016		December 31, 2015
Raw materials	$	801	$	775
Finished goods		1,101		637
Total inventories	$	1,902	$	1,412

Prepaid Expenses and Other Current Assets (Tables)

9 Months Ended

Sep. 30, 2016

Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]

Schedule of Prepaid Expenses and Other Current Assets

Prepaid expenses and other current assets consisted of the following:

	September 30, 2016		December 31, 2015
Prepaid insurance	$	443	$	297
Other prepaid expenses		613		370
Deposits and other current assets		106		119
Total prepaid expenses and other current assets	$	1,162	$	786

Intangible Assets and Goodwill (Tables)

9 Months Ended

Sep. 30, 2016

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Intangible Assets

The Company’s intangible assets at September 30, 2016 consisted of the following:

	Amortization
	periods			Accumulated						Net
	(in years)	Cost		amortization			Impairment			Carrying value
Patents	17-19 years	$	168	$	(6	)	$	-		$	162
Trademarks	Indefinite		201		-			-			201
Customer relationships	3-15 years		2,998		(488	)		(15	)		2,495
Trade name	5 years		16		(6	)		(1	)		9
Non-competition clause	3-4 years		294		(161	)		(20	)		113
State pharmacy licenses	25 years		45		(4	)		(28	)		13
		$	3,722	$	(665	)	$	(64	)	$	2,994

Schedule of Amortization Expenses for Intangible Assets

Amortization expense for intangible assets for the three and nine months ended September 30, 2016 was as follows:

	For the		For the		For the		For the
	Three Months Ended		Three Months Ended		Nine Months Ended		Nine Months Ended
	September 30, 2016		September 30, 2015		September 30, 2016		September 30, 2015
Patents	$	4	$	-	$	5	$	-
Customer relationships		60		66		191		195
Trade name		-		1		2		2
Non-competition clause		16		22		62		66
State pharmacy licenses		-		-		2		1
	$	79	$	88	$	262	$	264

Schedule of Estimated Future Amortization Expense

Estimated future amortization expense for the Company’s intangible assets at September 30, 2016 is as follows:

Remainder of 2016	$	90
2017		357
2018		216
2019		212
2020		210
Thereafter		1,908
	$	2,994

Schedule of Goodwill

Changes to the carrying value of the Company’s goodwill during the nine months ended September 30, 2016 was as follows:

Balance at December 31, 2015		2,466
Impairment related to Texas facility cessation		(239	)
Balance at September 30, 2016	$	2,227

Accounts Payable and Accrued Expenses (Tables)

9 Months Ended

Sep. 30, 2016

Payables and Accruals [Abstract]

Schedule of Accounts Payable and Accrued Expenses

Accounts payable and accrued expenses consisted of the following:

	September 30, 2016			December 31, 2015
Accounts payable	$	3,222		$	3,185
Deferred rent		429			63
Accrued interest (see Note 8)		108			90
Accrued exit fee for note payable (see Note 8)		500			500
Building lease liability(1)		121			46
Other accrued expenses (2)		-			23
Total accounts payable and accrued expenses		4,380			3,907
Less: Current portion		(3,795	)		(3,407	)
Non-current total accrued expenses	$	585		$	500

	(1)	In September 2014, the Company relocated its primary operations to a 7,565 square foot office facility in San Diego, California. In February 2015, the Company entered into a sublease agreement to sublet 3,874 square feet of its previously occupied offices through the remaining term of the lease at a monthly rent amount of $8. The Company recognized a loss of approximately $117 during the year ended December 31, 2014 related to the estimated remaining lease liability, net of expected sublease income, of the previously occupied offices. In September 2016, the Company decided to cease operations at its Texas location and started steps to wind down operations. The Company recognized a loss of $121 during the nine months ended September 30, 2016 related to the estimated remaining lease liability. The obligations were discounted based on current prevailing market rates.

	(2)	The amount consists of a $23 stock-based compensation accrual at December 31, 2015 related to stock options to be granted for consulting services provided. The stock options were granted during the nine months ended September 30, 2016 and the $23 was recorded to additional paid-in-capital.

Debt (Tables)

9 Months Ended

Sep. 30, 2016

Debt Disclosure [Abstract]

Summary of Notes Payable

Notes payable at September 30, 2016 was as follows:

	September 30, 2016
Senior Note - 2015	$	10,000
Convertible Senior Note - 2016		3,000
Add: Interest paid-in-kind		283
Less: Discount on notes		(3,553	)
Less: Current portion		-
Long-term portion	$	9,730

Summary of Future Minimum Payments

Future minimum payments as of September 30, 2016 are as follows:

	Amount

Remainder of 2016	$	437
2017		1,435
2018		2,981
2019		4,423
2020		4,424
Thereafter		5,711
Total minimum payments		19,411
Less: amount representing interest and interest paid-in-kind		(6,411	)
Notes payable, gross		13,000
Add: interest paid-in-kind		283
Less: unamortized discount		(3,553	)
Note payable and interest paid-in-kind, net of unamortized debt discount	$	9,730

Capital Lease Obligation (Tables)

9 Months Ended

Sep. 30, 2016

Leases [Abstract]

Schedule of Future Payment Under Captial Lease

The Company has also leased other equipment under capital leases with an interest rate of 4.25% per annum. At September 30, 2016, future payments under the Company’s capital leases were as follows:

	Amount
Remainder of 2016	$	194
2017		775
2018		773
2019		751
Total minimum lease payments		2,493
Less: amount representing interest payments		(590	)
Present value of future minimum lease payment		1,903
Less: current portion		(434	)
Less: unamortized discount		(30	)
Capital lease obligation, net of current portion and unamortized discount	$	1,439

Stockholders' Equity (Deficit) and Stock-Based Compensation (Tables)

9 Months Ended

Sep. 30, 2016

Schedule of Stock Option Plan Activity

A summary of stock option activity under the Plan for the nine months ended September 30, 2016 is as follows:

	Number of shares			Weighted Avg. Exercise Price		Weighted Avg. Remaining Contractual Life		Aggregate Intrinsic Value
Options outstanding - January 1, 2016		1,544,026		$	5.74
Options granted		502,350		$	4.02
Options exercised		(15,000	)	$	3.68
Options cancelled/forfeit		(60,313	)	$	8.02
Options outstanding - September 30, 2016		1,971,063			6.25		6.28	$	178,525
Options exercisable		760,071			6.26		5.86	$	176,250
Options vested and expected to vest		1,850,552			6.25		6.27	$	178,298

Schedule of Fair Value Assumption

The table below illustrates the fair value per share determined by the Black-Scholes-Merton option pricing model with the following assumptions used for valuing options granted to employees:

	2016
Weighted-average fair value of options granted	$	3.91
Expected terms (in years)		5.81 - 6.11
Expected volatility		101 - 107	%
Risk-free interest rate		1.07 - 1.70	%
Dividend yield		-

The table below illustrates the fair value per share determined by the Black-Scholes-Merton option pricing model with the following assumptions used for valuing options granted to consultants:

	2016
Weighted-average fair value of options granted	$	4.37
Expected terms (in years)		10.00
Expected volatility		104	%
Risk-free interest rate		1.14	%
Dividend yield		-

Schedule of Shares Outstanding and Exercisable

The following table summarizes information about stock options outstanding and exercisable at September 30, 2016:

	Options Outstanding						Options Exercisable
			Weighted
			Average		Weighted				Weighted
			Remaining		Average				Average
	Number		Contractual		Exercise		Number		Exercise
Range of Exercise Prices	Outstanding		Life in Years		Price		Exercisable		Price
$2.40		125,000		5.32	$	2.40		125,000	$	2.40
$3.74 - $4.50		678,123		7.89	$	4.06		194,005	$	4.29
$5.49 - $7.99		949,353		5.26	$	7.54		234,328	$	6. 80
$8.06 - $8.99		213,557		6.37	$	8.92		201,708	$	8.95
$42.80		5,030		3.87	$	42.80		5,030	$	42.80
		1,971,063		6.28	$	6.25		760,071	$	6.26

Schedule of Market-based Vesting Conditions for Restricted Stock Units Granted

These market-based accelerated vesting conditions and share amounts (in aggregate) are set forth below:

Tranche	Number of shares	Target share price
Tranche 1	230,000 shares	$9.00 or greater
Tranche 2	230,000 shares	$10.00 or greater
Tranche 3	230,000 shares	$12.00 or greater
Tranche 4	230,000 shares	$14.00 or greater
Tranche 5	287,500 shares	$15.00 or greater

Schedule of Assumptions Used

The Company used a lattice binomial model to estimate a derived service period of 33 months related to the performance-based vesting grants and used the following assumptions:

	2016
Market price	$	3.98
Contractual terms (in years)		5.00
Expected volatility		102	%
Risk-free interest rate		1.04	%
Dividend yield		-

Schedule of Restricted Stock Units Activity

A summary of the Company’s RSU activity and related information for the nine months ended September 30, 2016 is as follows:

	Number of RSUs			Weighted Average Grant Date Fair Value
RSUs unvested - January 1, 2016		1,487,961		$	3.18
RSUs granted		1,270,950		$	2.25
RSUs vested		(236,326	)	$	8.56
RSUs cancelled/forfeit		(1,217,017	)	$	1.95
RSUs unvested at September 30, 2016		1,305,568		$	2.45

Schedule of Warrants Activity

A summary of warrant activity for the nine months ended September 30, 2016 is as follows:

	Number of Shares Subject to Warrants Outstanding		Weighted Avg. Exercise Price

Warrants outstanding - January 1, 2016		240,688	$	7.41
Granted		40,000		3.75
Exercised		-
Expired		-
Warrants outstanding and exercisable - September 30, 2016		280,688	$	5.20
Weighted average remaining contractual life of the outstanding warrants in years - September 30, 2016		5.19

Schedule of Warrants Outstanding and Warrants Exercisable

A list of the warrants outstanding as of September 30, 2016 is included in the following table:

	Warrants Outstanding					Warrants Exercisable
		Warrants		Exercise		Warrants		Expiration
Warrant Series	Issue Date	Outstanding		Price		Exercisable		Date
Lender warrants (see Note 8)	5/11/2015		125,000	$	3.60		125,000		5/11/2025
Underwriter warrants	2/7/2013		55,688	$	5.25		55,688		2/7/2018
Settlement warrants	8/16/2016		40,000	$	3.75		40,000		8/16/2021
Warrants issued to investor relations consultant	7/19/2013		60,000	$	8.50		60,000		7/19/2018
			280,688	$	5.20		280,688

Schedule of Stock Based Compensation Granted to Employees Directors Consultants

The Company recorded stock-based compensation related to equity instruments granted to employees, directors and consultants as follows:

	For the		For the		For the		For the
	Three Months Ended		Three Months Ended		Nine Months Ended		Nine Months Ended
	September 30, 2016		September 30, 2015		September 30, 2016		September 30, 2015
Employees - selling and marketing	$	102	$	106	$	348	$	281
Employees - general and administrative		600		754		2,465		1,791
Directors - general and administrative		62		96		176		204
Consultants - selling and marketing		-		-		-		41
Other - general and administrative		115		-		115		-
Total	$	879	$	956	$	3,104	$	2,317

Warrant [Member]

Schedule of Fair Value Assumption

	2016
Weighted-average fair value of warrants granted		2.88
Expected terms (in years)		5
Expected volatility		106	%
Risk-free interest rate		0.79	%
Dividend yield		-

Derivative Instruments (Tables)

9 Months Ended

Sep. 30, 2016

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Schedule of Derivative Liabilities at Fair Value

The table below illustrates the fair value per share determined by the Black-Scholes-Merton option pricing model with the following assumptions used for valuing derivative liabilities:

	2016
Expected volatility	103 - 111	%
Risk-free interest rate	1.22 - 1.70	%
Dividend yield	-

Fair Value at Reconciliation of Measured Liabilities

The following table provides a reconciliation of all liabilities measured at fair value using Level 3 significant unobservable inputs:

	September 30, 2016
Warrant derivative liability:
Balance at January 1, 2016	$	-
Modification of warrant and reclassification from equity to liabilities		675
Change in fair value		(211	)
Reclassification from liabilities to equity upon closing of public equity offering		(464	)
Balance at June 30, 2016	$	-

Embedded conversion feature derivative liability:
Balance at January 1, 2016	$	-
Embedded conversion feature in Convertible Note issued		2,322
Change in fair value		324
Reclassification from liabilities to equity upon closing of public equity offering		(2,646	)
Balance at September 30, 2016	$	-

Summary of Significant Accounting Policies (Details Narrative) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015
Net loss	$ 3,850	$ 3,952	$ 12,985	$ 10,775
Accumulated deficit	70,749		70,749		$ 57,764
Net cash used in operating activities			8,977	7,842
Cash resources and restricted investments	2,812		2,812
Proceeds from sale and leaseback of equipment			841
Deposit coverage limits by FDIC, per owner			250
Cash deposits in excess of FDIC limits	2,111		2,111
Accounts receivable, net of allowance for doubtful accounts	272		272		180
Impairment of intangible assets and goodwill	303		$ 303
Restricted Stock Units [Member]
Number of shares vested during the period			281,283	39,880
Deferred Acquisition Obligations, Stock Options, Unvested RSUs and Warrants [Member]
Anti dilutive securities			4,424,397	3,382,512
Billing And Collection Agreement [Member] \| Third Party [Member]
Percentage of billing and collection amount			55.00%
Billing and collection management expense	0	$ 7	$ 24	$ 28
Due to related party	$ 30		$ 30		$ 81

Summary of Significant Accounting Policies - Schedule of Basic and Diluted Earnings Per Common Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Accounting Policies [Abstract]
Numerator - net loss	$ (3,850)	$ (3,952)	$ (12,985)	$ (10,775)
Denominator - weighted average number of shares outstanding, basic and diluted	13,471,004	9,603,541	12,404,328	9,501,730
Net loss per share, basic and diluted	$ (0.29)	$ (0.41)	$ (1.05)	$ (1.13)

Restricted Cash and Short-Term Investments (Details Narrative) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Cash and Cash Equivalents [Abstract]
Certificate of deposit	$ 450	$ 150

Inventories - Schedule of Inventories (Details) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Inventory Disclosure [Abstract]
Raw materials	$ 801	$ 775
Finished goods	1,101	637
Total inventories	$ 1,902	$ 1,412

Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Prepaid insurance	$ 443	$ 297
Other prepaid expenses	613	370
Deposits and other current assets	106	119
Total prepaid expenses and other current assets	$ 1,162	$ 786

Intangible Assets and Goodwill - Schedule of Intangible Assets (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2016 USD ($)
Cost	$ 3,722
Accumulated amortization	(665)
Impairment	(64)
Net Carrying value	2,994
Patents [Member]
Cost	168
Accumulated amortization	(6)
Impairment
Net Carrying value	$ 162
Patents [Member] \| Minimum [Member]
Amortization periods (in years)	17 years
Patents [Member] \| Maximum [Member]
Amortization periods (in years)	19 years
Trademarks [Member]
Amortization periods description	Indefinite
Cost	$ 201
Accumulated amortization
Impairment
Net Carrying value	201
Customer Relationships [Member]
Cost	2,998
Accumulated amortization	(488)
Impairment	(15)
Net Carrying value	$ 2,495
Customer Relationships [Member] \| Minimum [Member]
Amortization periods (in years)	3 years
Customer Relationships [Member] \| Maximum [Member]
Amortization periods (in years)	15 years
Trade Name [Member]
Amortization periods (in years)	5 years
Cost	$ 16
Accumulated amortization	(6)
Impairment	(1)
Net Carrying value	9
Non-Competition Clause [Member]
Cost	294
Accumulated amortization	(161)
Impairment	(20)
Net Carrying value	$ 113
Non-Competition Clause [Member] \| Minimum [Member]
Amortization periods (in years)	3 years
Non-Competition Clause [Member] \| Maximum [Member]
Amortization periods (in years)	4 years
State Pharmacy Licenses [Member]
Amortization periods (in years)	25 years
Cost	$ 45
Accumulated amortization	(4)
Impairment	(28)
Net Carrying value	$ 13

Intangible Assets and Goodwill - Schedule of Amortization Expenses for Intangible Assets (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Amortization of intangible assets	$ 79	$ 88	$ 262	$ 264
Patents [Member]
Amortization of intangible assets	4		5
Customer Relationships [Member]
Amortization of intangible assets	60	66	191	195
Trade Name [Member]
Amortization of intangible assets		1	2	2
Non-Competition Clause [Member]
Amortization of intangible assets	16	22	62	66
State Pharmacy Licenses [Member]
Amortization of intangible assets			$ 2	$ 1

Intangible Assets and Goodwill - Schedule of Estimated Future Amortization Expense (Details) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Remainder of 2016	$ 90
2017	357
2018	216
2019	212
2020	210
Thereafter	1,908
Intangible assets	$ 2,994	$ 3,135

Intangible Assets and Goodwill - Schedule of Goodwill (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2016 USD ($)
Intangible Assets And Goodwill - Schedule Of Goodwill Details
Balance beginning	$ 2,466
Impairment related to Texas facility cessation	(239)
Balance ending	$ 2,227

Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Expenses (Details) - USD ($)
$ in Thousands

Sep. 30, 2016

Dec. 31, 2015

Payables and Accruals [Abstract]

Accounts payable

$ 3,222

$ 3,185

Deferred rent

429

Accrued interest (see Note 8)

108

Accrued exit fee for note payable (see Note 8)

500

Building lease liability

^[1]

121

Other accrued expenses

^[2]

Total accounts payable and accrued expenses

4,380

3,907

Less: Current portion

(3,795)

(3,407)

Non-current total accrued expenses

$ 585

$ 500

[1]

(1) In September 2014, the Company relocated its primary operations to a 7,565 square foot office facility in San Diego, California. In February 2015, the Company entered into a sublease agreement to sublet 3,874 square feet of its previously occupied offices through the remaining term of the lease at a monthly rent amount of $8. The Company recognized a loss of approximately $117 during the year ended December 31, 2014 related to the estimated remaining lease liability, net of expected sublease income, of the previously occupied offices. In September 2016, the Company decided to cease operations at its Texas location and started steps to wind down operations. The Company recognized a loss of $121 during the nine months ended September 30, 2016 related to the estimated remaining lease liability. The obligations were discounted based on current prevailing market rates.

[2]

(2) The amount consists of a $23 stock-based compensation accrual at December 31, 2015 related to stock options to be granted for consulting services provided. The stock options were granted during the nine months ended September 30, 2016 and the $23 was recorded to additional paid-in-capital.

Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Expenses (Details) (Parenthetical) $ in Thousands	1 Months Ended	9 Months Ended	12 Months Ended
	Feb. 28, 2015 USD ($) ft²	Sep. 30, 2016 USD ($)	Dec. 31, 2014 USD ($)	Dec. 31, 2015 USD ($)	Sep. 30, 2014 ft²
Payables and Accruals [Abstract]
Area of office space \| ft²					7,565
Area of previous office space \| ft²	3,874
Monthly rent amount	$ 8
Recognized lease losses related to estimated remaining lease liability			$ 117
Lease liability		$ 121
Stock based compensation accrual				$ 23
Additional paid-in-capital		$ 23

Debt (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands				3 Months Ended		9 Months Ended
	Mar. 16, 2016	Jan. 22, 2016	May 11, 2015	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015
Loan due date	May 11, 2021
Liability of final fee included in accrued expenses				$ 500		$ 500		$ 500
Fair value of warrants							$ 840
Fair value of contractual term						5 years
Common stock volatility rate						102.00%
Fair value of dividend rate
Fair value of risk-free interest rate						1.04%
Debt discount						$ 829	175
Debt conversion price per share	$ 5.90			$ 5.90		$ 5.90
Proceeds from convertible note						$ 2,772
Warrants exercise price per share	$ 3.60
Loan Agreement [Member]
Debt discount				$ 110	$ 105	327	$ 175
Loan Agreement [Member] \| Life Sciences Alternative Funding LLC [Member]
Principal amount of loan			$ 10,000
Loans bear interest			12.50%
loans bear interest rate description			The term loans bear interest at a fixed per-annum rate of 12.5% and allows for 2% of the interest to be paid-in-kind until either February 2017 or May 2017,
Loan installments			36 months
Percentage of loan agreement final fee			5.00%
Loan due date			May 11, 2021
Incurred expense debt			$ 735
Liability of final fee included in accrued expenses			$ 500
Issuance of warrants to purchase maximum number of shares			125,000
Common stock exercise price per share			$ 7.85
Issuance of warrants to purchase of common stock expiration year			10 years
Fair value of warrants			$ 840
Fair value of common stock			$ 7.97
Fair value of contractual term			10 years
Common stock volatility rate			109.00%
Fair value of dividend rate			0.00%
Fair value of risk-free interest rate			1.25%
Loan Agreement [Member] \| Life Sciences Alternative Funding LLC [Member] \| Minimum Revenue or Cash Balance [Member]
Loan installments			24 months
Note Purchase Agreement [Member] \| Lender [Member] \| 8.00% Convertible Senior Secured Note [Member]
Loans bear interest		8.00%
Loan due date		May 11, 2021
Incurred expense debt		$ 228
Debt discount				$ 155		$ 464
Convertible note principal amount		$ 3,000
Convertible note fixed per annum rate		8.00%
Convertible note description		The Company is permitted to redeem the Convertible Note prior to its maturity at any time on or after March 1, 2018 for cash purchase prices equal to 109% - 105% of the outstanding principal amount of the Convertible Note, depending on the date of redemption.
Debt conversion price per share		$ 5.90
Proceeds from convertible note		$ 3,000
Percentage of repurchase convertible note in cash is greater than outstanding principal amount		105.00%
Fair value of embedded conversion feature		$ 2,322

Debt - Summary of Notes Payable (Details) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Less: Discounts on notes	$ 30
Long-term portion	8,816	$ 8,336
Senior Note - 2015 [Member]
Notes payable	10,000
Convertible Senior Note - 2016 [Member]
Notes payable	3,000
Notes Payable [Member]
Notes payable	13,000
Add: Interest paid-in-kind	283
Less: Discounts on notes	(3,553)
Less: Current portion
Long-term portion	$ 9,730

Debt - Summary of Future Minimum Payments (Details) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Less: unamortized discount	$ 30
Notes payable and interest paid-in-kind, net of unamortized debt discount	8,816	$ 8,336
Notes Payable [Member]
Remainder of 2016	437
2017	1,435
2018	2,981
2019	4,423
2020	4,424
Thereafter	5,711
Total minimum payments	19,411
Less: amount representing interest and interest paid-in-kind	(6,411)
Notes payable, gross	13,000
Add: interest paid-in-kind	283
Less: unamortized discount	(3,553)
Notes payable and interest paid-in-kind, net of unamortized debt discount	$ 9,730

Capital Lease Obligation (Details Narrative) - USD ($)		3 Months Ended	9 Months Ended
Capital Lease Obligation (Details Narrative) - USD ($)	Aug. 09, 2016	Sep. 30, 2016	Sep. 30, 2016	Sep. 30, 2015
Property and equipment purchase price			$ 6,540,000	$ 704,000
Amortization of debt discount			829,000	$ 175,000
Lease Agreement [Member]
Property and equipment purchase price	$ 2,000		2,000
Lease monthly payments	$ 64
Lease future payment			300,000
Lease incurred expenses			$ 67,000
Capital lease future minimum payments percentage		16.80%	16.80%
Amortization of debt issuance costs at a rate			1.80%
Amortization of debt discount		$ 37,000	$ 37,000
Capital leases interest rate			4.25%

Capital Lease Obligation - Schedule of Future Payment Under Captial Lease (Details) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Leases [Abstract]
Remainder of 2016	$ 194
2017	775
2018	773
2019	751
Total minimum lease payments	2,493
Less: amount representing interest payments	(590)
Present value of future minimum lease payment	1,903
Less: current portion	(434)	$ (21)
Less: unamortized discount	(30)
Capital lease obligation, net of current portion and unamortized discount	$ 1,439	$ 1

Stockholders' Equity (Deficit) and Stock-Based Compensation (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands				1 Months Ended			3 Months Ended	9 Months Ended
	May 31, 2016	Apr. 30, 2016	Mar. 16, 2016	Sep. 30, 2016	May 31, 2016	Nov. 30, 2015	Sep. 30, 2016	Sep. 30, 2016	Sep. 30, 2015
Sale of stock price per share				$ 3.81			$ 3.81	$ 3.81
Proceeds from offering price								$ 11,088
Net proceeds from sales of common stock								$ 195
Shares issued upon exercise of stock options, shares								15,000
Shares issued upon exercise of stock options								$ 55
Stock options to purchase shares of common stock								15,000
Stock option purchase of exercise price								$ 3.68
Preferred stock, shares authorized				5,000,000			5,000,000	5,000,000
Preferred stock, par value				$ 0.001			$ 0.001	$ 0.001
Preferred stock, shares issued				0			0	0
Preferred stock, shares outstanding				0			0	0
Intrinsic value of stock option exercised								$ 29
Stock options granted with exercise price contractual terms								10 years
Stock options granted vesting terms								During the six months ended June 30, 2016, the Company granted stock options to certain employees and consultants. The stock options were granted with an exercise price equal to the current market price of the Company’s common stock, as reported by the securities exchange on which the common stock was then listed, at the grant date and have contractual terms of 10 years. Vesting terms for options granted to employees and consultants during the six months ended June 30, 2016 typically included one of the following vesting schedules: 25% of the shares subject to the option vest and become exercisable on the first anniversary of the grant date and the remaining 75% of the shares subject to the option vest and become exercisable quarterly in equal installments thereafter over three years; or 100% vesting associated with the provision or completion of services provided under contracts with consultants. Certain option awards provide for accelerated vesting if there is a change in control (as defined in the Plan) and in the event of certain modifications to the option award agreement.
Percentage of forfeiture factor								10.00%
Stock-based compensation								$ 2,989	$ 2,317
Stock Options [Member]
Unrecognized compensation expense related to unvested stock options granted under the Plan				$ 5,111			$ 5,111	$ 5,111
Expense expected to recognize over the weighted-average remaining vesting period								3 years 3 months 18 days
Stock-based compensation							$ 471	$ 1,772
2007 Incentive Stock and Awards Plan [Member]
Maximum number of common stock issuance under the plan				5,000,000			5,000,000	5,000,000
Restricted Stock Units [Member]
Number of shares vested during the period								281,283	39,880
Unrecognized compensation expense related to unvested stock options granted under the Plan				$ 3,874			$ 3,874	$ 3,874
Expense expected to recognize over the weighted-average remaining vesting period								2 years
Stock-based compensation							313	$ 1,237
Performance shares grant period		5 years
Restricted Stock Units [Member] \| Minimum [Member]
Performance shares price per share		$ 9
Restricted Stock Units [Member] \| Maximum [Member]
Performance shares price per share		$ 15
Pharmacy Creations, LLC [Member]
Number of shares vested during the period					75,000
Issuance of common stock to settle contingent acquisition					$ 302
Mark L. Baum [Member] \| Restricted Stock Units [Member]
Performance shares	1,050,000	1,050,000
Mark L. Baum [Member] \| Restricted Stock Units [Member]
Number of shares vested during the period					200,000
Directors [Member] \| Restricted Stock Units [Member]
Number of shares vested during the period								33,154
Andrew R. Boll [Member] \| Restricted Stock Units [Member]
Performance shares	157,500	157,500
Sales Agreement [Member]
Number of shares sold under the agreement				48,642
Percentage of cash commission						3.00%
Proceeds from offering price				$ 2,625
Net proceeds from sales of common stock				195
Available for future sales of shares				1,885			$ 1,885	$ 1,885
Sales commission and offering expenses				$ 16
Underwriting Agreement [Member]
Number of common stock shares issued for offering								3,335,000
Sale of stock price per share			$ 3.60
proceeds from sale of common stock approximately			$ 11,088

Stockholders' Equity (Deficit) and Stock-Based Compensation - Schedule of Stock Option Plan Activity (Details) $ / shares in Units, $ in Thousands	9 Months Ended
	Sep. 30, 2016 USD ($) $ / shares shares
Number of shares, Options exercised \| shares	15,000
Weighted Avg. Exercise Price, Options granted	$ 3.68
Weighted Avg. Exercise Price, Exercisable Ending Balance	$ 6.25
Weighted Avg. Remaining Contractual Life, Options exercisable	10 years
Stock Option Plan [Member]
Number of shares, Outstanding, Beginning balance \| shares	1,544,026
Number of shares, Options granted \| shares	502,350
Number of shares, Options exercised \| shares	(15,000)
Number of shares, Options cancelled/forfeit \| shares	(60,313)
Number of shares, Outstanding, Ending balance \| shares	1,971,063
Number of shares, Options exercisable \| shares	760,071
Number of shares, Options vested and expected to vest \| shares	1,850,552
Weighted Avg. Exercise Price, Outstanding, Beginning balance	$ 5.74
Weighted Avg. Exercise Price, Options granted	4.02
Weighted Avg. Exercise Price, Options exercised	3.68
Weighted Avg. Exercise Price, Options cancelled/forfeit	8.02
Weighted Avg. Exercise Price, Outstanding, Ending balance	6.25
Weighted Avg. Exercise Price, Exercisable Ending Balance	6.26
Weighted Avg. Exercise Price, Vested and expected to vest - end of period	$ 6.25
Weighted Avg. Remaining Contractual Life, Options outstanding	6 years 3 months 11 days
Weighted Avg. Remaining Contractual Life, Options exercisable	5 years 10 months 10 days
Weighted Avg. Remaining Contractual Life, Options vested and expected to vest	6 years 3 months 7 days
Aggregate Intrinsic Value, Options outstanding \| $	$ 178,525
Aggregate Intrinsic Value, Options exercisable \| $	176,250
Aggregate Intrinsic Value, Options vested and expected to vest \| $	$ 178,298

Stockholders' Equity (Deficit) and Stock-Based Compensation - Schedule of Fair Value Assumption (Details)	9 Months Ended
	Sep. 30, 2016 $ / shares
Options Granted To Employees [Member]
Weighted-average fair value of granted	$ 3.91
Expected volatility, minimum	101.00%
Expected volatility, maximum	107.00%
Risk-free interest rate, minimum	1.07%
Risk-free interest rate, maximum	1.70%
Dividend yield
Options Granted To Employees [Member] \| Minimum [Member]
Expected terms (in years)	5 years 9 months 22 days
Options Granted To Employees [Member] \| Maximum [Member]
Expected terms (in years)	6 years 1 month 10 days
Options Granted To Consultants [Member]
Weighted-average fair value of granted	$ 4.37
Expected terms (in years)	10 years
Expected volatility	104.00%
Risk-free interest rate	1.14%
Dividend yield
Warrant Granted [Member]
Weighted-average fair value of granted	$ 2.88
Expected terms (in years)	5 years
Expected volatility	106.00%
Risk-free interest rate	0.79%
Dividend yield

Stockholders' Equity (Deficit) and Stock-Based Compensation - Schedule of Shares Outstanding and Exercisable (Details)	9 Months Ended
	Sep. 30, 2016 $ / shares shares
Number of Options Outstanding \| shares	1,971,063
Weighted Average Remaining Contractual Life in Years	6 years 3 months 11 days
Weighted Average Exercise Price	$ 6.25
Number Exercisable \| shares	760,071
Weighted Average Exercisable Exercise Price	$ 6.26
Range One [Member]
Range of Exercise Prices, minimum	$ 2.40
Number of Options Outstanding \| shares	125,000
Weighted Average Remaining Contractual Life in Years	5 years 3 months 26 days
Weighted Average Exercise Price	$ 2.40
Number Exercisable \| shares	125,000
Weighted Average Exercisable Exercise Price	$ 2.40
Range Two [Member]
Range of Exercise Prices, minimum	3.74
Range of Exercise Prices, maximum	$ 4.50
Number of Options Outstanding \| shares	678,123
Weighted Average Remaining Contractual Life in Years	7 years 10 months 21 days
Weighted Average Exercise Price	$ 4.06
Number Exercisable \| shares	194,005
Weighted Average Exercisable Exercise Price	$ 4.29
Range Three [Member]
Range of Exercise Prices, minimum	5.49
Range of Exercise Prices, maximum	$ 7.99
Number of Options Outstanding \| shares	949,353
Weighted Average Remaining Contractual Life in Years	5 years 3 months 4 days
Weighted Average Exercise Price	$ 7.54
Number Exercisable \| shares	234,328
Weighted Average Exercisable Exercise Price	$ 6.80
Range Four [Member]
Range of Exercise Prices, minimum	8.06
Range of Exercise Prices, maximum	$ 8.99
Number of Options Outstanding \| shares	213,557
Weighted Average Remaining Contractual Life in Years	6 years 4 months 13 days
Weighted Average Exercise Price	$ 8.92
Number Exercisable \| shares	201,708
Weighted Average Exercisable Exercise Price	$ 8.95
Range Five [Member]
Range of Exercise Prices, minimum	$ 42.80
Number of Options Outstanding \| shares	5,030
Weighted Average Remaining Contractual Life in Years	3 years 10 months 13 days
Weighted Average Exercise Price	$ 42.80
Number Exercisable \| shares	5,030
Weighted Average Exercisable Exercise Price	$ 42.80

Stockholders' Equity (Deficit) and Stock-Based Compensation - Schedule of Market-based Vesting RSU Granted (Details)	9 Months Ended
	Sep. 30, 2016 shares
Tranche 1 [Member]
Number of shares vesting	230,000
Target share price description	9.00 or greater
Tranche 2 [Member]
Number of shares vesting	230,000
Target share price description	10.00 or greater
Tranche 3 [Member]
Number of shares vesting	230,000
Target share price description	12.00 or greater
Tranche 4 [Member]
Number of shares vesting	230,000
Target share price description	14.00 or greater
Tranche 5 [Member]
Number of shares vesting	287,500
Target share price description	15.00 or greater

Stockholders' Equity (Deficit) and Stock-Based Compensation - Schedule of Assumptions Used (Details)	9 Months Ended
	Sep. 30, 2016 $ / shares
Equity [Abstract]
Market price	$ 3.98
Contractual terms (in years)	5 years
Expected volatility	102.00%
Risk-free interest rate	1.04%
Dividend yield

Stockholders' Equity (Deficit) and Stock-Based Compensation - Schedule of Restricted Stock Units Activity (Details) - Restricted Stock Units [Member]	9 Months Ended
	Sep. 30, 2016 $ / shares shares
Number of RSUs unvested, Outstanding, Beginning balance \| shares	1,487,961
Number of RSUs granted \| shares	1,270,950
Number of RSUs vested \| shares	(236,326)
Number RSUs cancelled/forfeit \| shares	(1,217,017)
Number of RSUs unvested, Outstanding, Ending balance \| shares	1,305,568
Weighted Average Grant Date Fair Value, Beginning balance \| $ / shares	$ 3.18
Weighted Average Grant Date Fair Value, RSUs granted \| $ / shares	2.25
Weighted Average Grant Date Fair Value, RSUs vested \| $ / shares	8.56
Weighted Average Grant Date Fair Value, RSUs cancelled/forfeit \| $ / shares	1.95
Weighted Average Grant Date Fair Value, Ending balance \| $ / shares	$ 2.45

Stockholders' Equity (Deficit) and Stock-Based Compensation - Schedule of Warrants Activity (Details) - Warrant [Member]	9 Months Ended
	Sep. 30, 2016 $ / shares shares
Number of shares, outstanding, beginning balance \| shares	240,688
Number of shares subject to warrants outstanding, granted \| shares	40,000
Number of shares subject to warrants outstanding, exercised \| shares
Number of shares subject to warrants outstanding, expired \| shares
Number of shares, outstanding, ending balance \| shares	280,688
Weighted average remaining contractual life of the outstanding warrants in years	5 years 2 months 9 days
Weighted avg. Exercise price, outstanding, beginning balance \| $ / shares	$ 7.41
Weighted avg. Exercise price, granted \| $ / shares	3.75
Weighted avg. Exercise price, exercised \| $ / shares
Weighted avg. Exercise price, expired/forfeited \| $ / shares
Weighted avg. Exercise price, outstanding, ending balance \| $ / shares	$ 5.20

Stockholders' Equity (Deficit) and Stock-Based Compensation - Schedule of Warrants Outstanding and Warrants Exercisable (Details) - $ / shares		9 Months Ended
	Mar. 16, 2016	Sep. 30, 2016
Exercise Price	$ 3.60
Expiration Date	May 11, 2025
Warrant [Member]
Warrants Outstanding		280,688
Exercise Price		$ 5.20
Warrants Exercisable		280,688
Lender Warrants [Member]
Issue Date		May 11, 2015
Warrants Outstanding		125,000
Exercise Price		$ 3.60
Warrants Exercisable		125,000
Expiration Date		May 11, 2025
Underwriter Warrants [Member]
Issue Date		Feb. 07, 2013
Warrants Outstanding		55,688
Exercise Price		$ 5.25
Warrants Exercisable		55,688
Expiration Date		Feb. 07, 2018
Settlement Warrants [Member]
Issue Date		Aug. 16, 2016
Warrants Outstanding		40,000
Exercise Price		$ 3.75
Warrants Exercisable		40,000
Expiration Date		Aug. 16, 2021
Warrants Issued To Investor Relations Consultant [Member]
Issue Date		Jul. 19, 2013
Warrants Outstanding		60,000
Exercise Price		$ 8.50
Warrants Exercisable		60,000
Expiration Date		Jul. 19, 2018

Stockholders' Equity (Deficit) and Stock-Based Compensation - Schedule of Stock Based Compensation Granted to Employees Directors Consultants (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Stock based compensation related to equity instruments granted to related parties	$ 879	$ 956	$ 3,104	$ 2,317
Employees [Member] \| Selling And Marketing [Member]
Stock based compensation related to equity instruments granted to related parties	102	106	348	281
Employees [Member] \| General And Administrative [Member]
Stock based compensation related to equity instruments granted to related parties	600	754	2,465	1,791
Directors [Member] \| General And Administrative [Member]
Stock based compensation related to equity instruments granted to related parties	62	96	176	204
Consultants [Member] \| Selling And Marketing [Member]
Stock based compensation related to equity instruments granted to related parties				41
Other [Member] \| General And Administrative [Member]
Stock based compensation related to equity instruments granted to related parties	$ 115		$ 115

Derivative Instruments (Details Narrative) - $ / shares	Mar. 16, 2016	Sep. 30, 2016
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Debt conversion price per share	$ 5.90	$ 5.90
Warrants exercise price per share	$ 3.60
Warrants expiration date	May 11, 2025
Convertible note matures date	May 11, 2021

Derivative Instruments - Schedule of Derivative Liabilities at Fair Value (Details)	9 Months Ended
	Sep. 30, 2016
Expected volatility	102.00%
Risk-free interest rate	1.04%
Dividend yield
Minimum [Member]
Expected volatility	103.00%
Risk-free interest rate	1.22%
Maximum [Member]
Expected volatility	111.00%
Risk-free interest rate	1.70%

Derivative Instruments - Fair Value at Reconciliation of Measured Liabilities (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2016 USD ($)
Warrant Derivative Liability [Member]
Balance Beginning
Modification of warrant and reclassification from equity to liabilities	675
Change in fair value	(211)
Reclassification from liabilities to equity upon closing of public equity offering	(464)
Balance Ending
Embedded Conversion Feature Derivative Liability [Member]
Balance Beginning
Embedded conversion feature in Convertible Note issued	2,322
Change in fair value	324
Reclassification from liabilities to equity upon closing of public equity offering	(2,646)
Balance Ending

Commitments and Contingencies (Details Narrative) $ in Thousands				3 Months Ended		9 Months Ended		12 Months Ended
	Aug. 31, 2016 shares	May 31, 2016 USD ($) shares	Apr. 02, 2014 USD ($) shares	Sep. 30, 2016 USD ($)	Sep. 30, 2015 USD ($)	Sep. 30, 2016 USD ($)	Sep. 30, 2015 USD ($)	Sep. 30, 2016 USD ($)	Apr. 30, 2016 USD ($)	Dec. 31, 2015 USD ($)
Number of common stock shares issued for maximum exceeds from revenue \| shares	40,000
Fair value of contingent acquisition obligation										$ 483
Issuance of common stock to settle contingent acquisition obligation						$ 302
Non-cash gain on contingent acquisition obligation				$ 0		83	31
Gain on settlement						551
Insurance claim in other income				861		861
Insurance claim payment						20
Insurance receivable				841		841		$ 841
Asset purchase, license and commission expense				$ 91	$ 48	$ 452	$ 50
Pharmacy Creations, LLC [Member]
Revenue		$ 100
Fair value of divided ratio			18.5882
Number of common stock shares issued for maximum exceeds from revenue \| shares		75,000	215,190
Pharmacy Creations, LLC [Member] \| Minimum [Member]
Revenue								3,500
Number of common stock shares issued for exceeds revenue value			$ 3,500
Pharmacy Creations, LLC [Member] \| Maximum [Member]
Revenue								$ 7,500
Urigen Pharmaceuticals, Inc. [Member] \| License Agreement [Member]
Unpaid royalties									$ 698

Segment Information and Concentrations (Details Narrative)	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Segment Reporting [Abstract]
Maximum percentage of sales derived from single customer			10.00%	10.00%
Percentage of drug and chemical purchases from three main suppliers	76.00%	49.00%	72.00%	55.00%

Subsequent Events (Details Narrative) - USD ($) $ in Thousands		1 Months Ended		3 Months Ended	9 Months Ended
	Nov. 30, 2016	Nov. 30, 2016	Oct. 31, 2016	Sep. 30, 2016	Sep. 30, 2016	Sep. 30, 2015
Proceeds from sale of common stock					$ 195
Gain on settlement					551
Insurance claim in other income				$ 861	861
Insurance claim payment					20
Subsequent Event [Member]
Gain on settlement					551
Insurance claim in other income	$ 861
Insurance claim payment	44	$ 840			$ 20
Property damage	818
Insurance deduction value	$ 1
Subsequent Event [Member] \| Sales Agreement [Member]
Number of common stock sold					8,400
Proceeds from sale of common stock					$ 18
Deducting sales commission and offering expenses				$ 1	$ 1
Subsequent Event [Member] \| Restricted Stock Units [Member] \| Non-employee Director [Member]
Number of common stock issued			16,076